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ABSTRACT OF DISSERTATION 
 
 
THE GENETIC REGULATION OF THE RESPONSE OF HEMATOPOIETIC 
STEM/PROGENITOR CELLS TO THE CYTOSTATIC AGENT HYDROXYUREA 
 
 Cellular proliferation is a key characteristic of hematopoietic stem and progenitor 
cells (HSC/HPCs) that allows for the production of all blood cell lineages during an 
individual’s lifetime.  While this feature of stem cells is strictly regulated during steady-
state and stress hematopoiesis, it also contributes to the development of 
myeloproliferative disorders, such as chronic myelogenous leukemia, essential 
thrombocythemia, and polycythemia vera.  It should come as no surprise then, that 
common treatments for these diseases often target the proliferative nature of the 
dysfunctional HSC/HPCs.  Thus, the identification of molecular determinants of cell 
cycle regulation associated with these disorders could serve as targets for novel therapies. 
 Using the hematopoietic system of the inbred mouse strains, C57BL/6J (B6) and 
DBA/2J (D2), it was found that the HSC/HPCs of the long-lived B6 mouse strain were 
less susceptible to the cytostatic agent hydroxyurea (HU) than the short-lived D2 mouse 
strain.  A quantitative trait locus (QTL) analysis revealed a region of proximal 
chromosome 7 that regulates this response to HU.  Congenic mouse strains were 
generated and phenotypic analysis confirmed that the B6 and D2 loci confer a low and 
high sensitivity of the HSC/HPCs to HU, respectively.  We then showed that while this 
response of the HSC/HPCs to HU is independent of their cell cycle status, the B6 allele 
of this QTL confers a proliferative advantage to bone marrow cells after bone marrow 
transplantation.    
 Having shown that proximal chromosome 7 regulates the response of HSC/HPCs 
to HU, we found it necessary to characterize the gene and protein expression profiles in 
order to identify the responsible candidate genes.  We first analyzed mRNA expression 
profiles of HPCs from the parental and congenic mouse strains using gene microarrays 
and found that four genes within the congenic interval were differentially expressed.  
Real-time PCR confirmed that the expression profile of only one gene, Ndufa3, is 
significantly different in HPCs of B6 and D2 mice.  Concurrently, we assessed the 
protein expression profiles of HPC-enriched mononuclear cells.  Significant differences 
  
were found between the cytoplasmic and nuclear fractions of both strains, with a skewing 
of protein expression towards the D2 congenic strain.   
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CHAPTER ONE 
Introduction 
Characteristics of the hematopoietic system 
 The production of over 4 x 1015 erythrocytes, lymphocytes, and myeloid cells 
during the lifetime of an individual rests on the shoulders of the hematopoietic stem cell 
(HSC) (Lansdorp 1998).  While the demand placed upon the HSC may seem Sisyphean 
in its magnitude, it is hardly a futile endeavor.  For instance, a single HSC can repopulate 
the entire hematopoietic system of a lethally irradiated mouse and engraftment levels 
after secondary transplantation mirror those of the primary recipients (Osawa, Hanada et 
al. 1996; Krause, Theise et al. 2001).  While other transplantation protocols show that the 
numbers of primitive cells in the bone marrow (BM) of recipients remain depressed 
permanently, circulating blood cell numbers are not significantly different from non-
transplanted mice (Iscove and Nawa 1997).  This is a profound statement of the ability of 
these pluripotent stem cells to proliferate, differentiate, and self-renew.  Furthermore, BM 
cells can be serially transplanted up to five times before the marrow grafts fail to sustain 
hematopoiesis (Siminovitch, Till et al. 1964; Ogden and Micklem 1976).  The 
transplantation process places extreme demand on the HSC population that is not 
encountered during normal aging, which leads to the suggestion that mouse BM cells 
have sufficient proliferative capacity to sustain hematopoiesis over multiple mouse life 
spans (Harrison, Astle et al. 1978; Harrison and Astle 1982).  Even more confounding is 
the finding by our laboratory and others that the absolute number of HSCs does not 
decrease but actually increases during the lifetime of the widely used C57BL/6 (B6) 
mouse strain (Morrison, Wandycz et al. 1996; de Haan, Nijhof et al. 1997; Sudo, Ema et 
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al. 2000).  Indeed, even human studies have shown that the ability of HSCs to support 
hematopoiesis throughout life is reflected by the constancy of mature blood cell counts 
(Marley, Lewis et al. 1999; Bagnara, Bonsi et al. 2000).  Thus, HSCs seem to be able to 
fulfill their proliferative obligation over an entire lifetime.   
 
Organization and identification of the pluripotent HSC 
 The hematopoietic system is arguably the best studied and most well defined stem 
cell driven tissue in mammalian physiology.  Initial studies, which relied  on the ability of 
a bone marrow transplant to rescue lethally irradiated mice from bone marrow failure, 
indicated that a population of stem cells exist in the bone marrow that could give rise to 
all of the blood cell lineages (Lorenz, Uphoff et al. 1951).  For many years this 
population of cells remained elusive until it was discovered that clonogenic nodules 
formed on the spleens of mice receiving bone marrow transplants (Till and McCulloch 
1961).  When the cells were isolated and used to engraft secondary transplant recipients, 
these cells were found to have the ability to contribute to hematopoiesis (Lewis and 
Trobaugh 1964).  These spleen colony forming units (CFU-S) remained a standard of 
HSC identification for many years.  The problem remained, though, that this was still a 
relatively heterogeneous population.  In other words, this population had both stem and 
progenitor cell activity as defined by the ability to provide both long- (>12 weeks) and 
short-term (<12 weeks) hematopoiesis, respectively.  In the meantime, the advent of flow 
cytometry hastened a search for cellular markers of stem cell activity that would allow for 
the physical separation of HSCs from the bone marrow (Srour and Yoder 2005).  To date, 
a consensus definition of the HSC, whether by functional assays or cell surface 
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phenotype, has been difficult to attain within the scientific community.  This difficulty 
arises because most assays used to study HSCs rely on their clonogenic capacity, e.g. 
CFU-S formation or peripheral blood cell production after BM transplantation.  In other 
words, the very cells  being studied are lost due to the induction of proliferation and 
differentiation necessary for colony formation.  Recent investigations have thus focused 
on applying these assays to BM subpopulations that are enriched and/or depleted for cell 
surface proteins.  These cell surface antigens commonly consist of the c-kit receptor and 
stem cell antigen 1 (Sca-1) on a background that is devoid of lineage markers for 
differentiated cells, such as granulocytes, B cells, T cells, etc. (LIN-Sca1+ckit+ or LSK).  
Furthermore, hematopoietic progenitor cells (HPCs) can similarly be assayed as LIN-
Sca1-ckit+ (Shizuru, Negrin et al. 2005).  It should be cautioned, however, that these 
definitions refer to enriched, not purified, cell populations.  Thus, for the purposes of this 
discussion HSCs and HPCs will be used interchangeably.   
 
Systemic versus cellular aging 
 What is aging?  When does it begin?  What are its targets?  These are questions 
for which there are no easy answers.  For instance, does aging begin at birth at which 
point development has culminated in an independently functioning individual, or does it 
begin at puberty when the individual has attained reproductive maturity, the putative 
endpoint of natural selection (Schlessinger and Ko 1998)?  Furthermore, we can ask at 
what level does the aging process occur.  It has been proposed that there are two separate 
yet not necessarily mutually exclusive general levels of organismal aging – systemic and 
cell-autonomous.  Systemic aging has been more formally proposed as the hormonal 
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control of aging, where changes in humoral factors with age can cause system-wide 
changes in the homeostatic condition (Wise, Krajnak et al. 1996).  Support for this idea 
has gained traction from studies of mice expressing a mutant form of the KLOTHO gene 
encoding a protein hormone that leads to phenotypic changes characteristic of accelerated 
aging (Kuro-o, Matsumura et al. 1997).  Conversely, when the wild-type KLOTHO gene 
is overexpressed in mice it leads to a modest yet significant increase in both male and 
female lifespan (Kurosu, Yamamoto et al. 2005).  The cell-autonomous theory on the 
other hand posits that individual cells are the targets of the aging process, via a time-
dependent increase in homeostatic dysfunction.  The potential mechanisms include 
increases in the production of reactive oxygen species, telomere shortening and, not 
surprisingly, genomic instability.  An implication of this theory is that long-lived cells in 
the organism, such as neurons, muscle, and importantly stem cells, would be the 
predominant substrates of aging, while those cells that undergo rapid and continuous 
turnover would be removed before they could exert an effect on tissue function.  Here, 
we take the view that aging targets the cell-intrinsic processes necessary for maintenance 
of tissue and thus organismal function.  Specifically, we define aging as the detrimental 
and irreversible changes that occur during a cell’s lifetime that lead to the inability of the 
resident tissue to maintain homeostasis at both steady-state levels and in response to 
stress.  Importantly, this definition could also apply to the cellular changes that lead to 
carcinogenesis, a process bearing some of the common principles of aging.  The fact that 
the incidence of most types of cancer escalates rapidly after the age of 65 and arises from 
accumulated genomic lesions is evidence that cancer is a manifestation of the aging 
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process (Edwards, Brown et al. 2005).  Thus, the changes in cellular biology that occur 
during oncogenesis should also be evident, in part, during successful aging.    
 
Model systems of stem cell aging 
 The field of hematology has benefited immensely from the study of a wide variety 
of organisms.  Studies of invertebrate systems such as C. elegans and D. melanogaster 
have yielded keen insight into stem cell biology and mechanisms of aging, but it has 
predominantly been the study of the mammalian hematopoietic system that has led to the 
current understanding of the physiology of hematopoiesis.  The utilization of mouse 
genetics has only recently been fully realized as a tool as it was this mammalian model 
that yielded the breakthrough discoveries of Till and McCulloch (Till and McCulloch 
1961).  Most studies on the aging of HSCs have used the B6 strain due to its utility as a 
model for transplantation studies via the polymorphic CD45 locus.  However, we now 
know that the B6 mouse strain is not necessarily representative of all other inbred mouse 
strains.  We and others have shown that the HSCs of B6 mice differ markedly from other 
strains in proliferative kinetics, homing and engraftment properties, and pool size with 
age (Harrison 1983; Van Zant, Holland et al. 1990; Chen, Astle et al. 1999).  In addition, 
the B6 mouse strain is one of the longest-lived mouse strains with a mean lifespan of 3 
years versus other mouse strains with mean lifespan from 1.5-2 years. Therefore, it is 
evident that the genetic background of a particular mouse strain can have a profound 
effect on the biology of the HSC population as well as organismal longevity.  Indeed, it is 
for this reason that it is difficult to compare findings from various laboratories where 
different mouse strains are used.  Furthermore, caution must be exercised when 
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attempting to extrapolate findings in homozygous laboratory mice to genetically 
heterogeneous humans.   
 
 The identification and study of human HSCs have significantly lagged that of 
mouse and other mammalian HSCs primarily due to the difficulty in obtaining significant 
amounts of BM, particularly from very old donors.  Furthermore, the field was hampered 
early on by the reliance on in vitro clonogenic assays of putative HSC function in the 
absence of reliable in vivo model systems such as those used by mouse researchers.  A 
significant development in this regard has been the creation of severe combined immune 
deficient (SCID) mice that are able to support human HSC-derived hematopoiesis 
following BM transplant (Dick 1996).  These mice have yielded key insights into the 
structure of the human hematopoietic hierarchy as well as the conservation of 
hematopoietic regulation between mouse and man.  However, study of the long term 
repopulating and self-renewal ability ascribed to HSCs, particularly as they relate to 
aging, is hampered by the large cell doses necessary for engraftment, the delayed time 
course of engraftment, and the relatively short repopulating period (Dick 1996; Dick, 
Guenechea et al. 2001).   
 
Regulation of HSC proliferation    
 A current model of HSC-directed hematopoiesis is based on the principle that one 
or at most a few HSCs of a highly quiescent population divide to produce highly 
proliferative progenitors with restricted developmental potential.  These lineage restricted 
transit-amplifying cells bear the proliferative load necessary for the production of the 
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repertoire of cell types found in the peripheral blood. Thus, the ability of HSCs to carry 
out the demands of hematopoiesis hinges on their ability to proliferate in response to both 
intrinsic and extrinsic cues.  This clonal selection theory of hematopoiesis (Kay 1965) is 
supported by studies showing that when retrovirally marked HSCs were transplanted into 
a conditioned host, only a few clones contributed to mature blood cell production (Dick, 
Magli et al. 1985; Jordan and Lemischka 1990).  This observation was confirmed by Van 
Zant et al. (Van Zant, Chen et al. 1991) who, using the same retroviral marking strategy 
in B6-D2 chimeric mice, also showed the involvement of only a few clones in carrying 
out hematopoiesis.  However, recent evidence suggests that the integration of these 
retroviral vectors into the DNA is not necessarily neutral in their effect on the fitness of 
the transformed cells.  For example, the integration sites of clonally dominant HSCs often 
encode regulatory regions involved in the processes of HSC self renewal and survival 
(Kustikova, Fehse et al. 2005).  Furthermore, the transplantation studies that demonstrate 
oligoclonal hematopoiesis may not be representative of steady-state hematopoiesis in an 
unperturbed animal.  Finally, when mice were continuously administered BrdU in their 
drinking water, the entire population of HSCs completed at least one round of replication 
within a two-month time period (Pietrzyk, Priestley et al. 1985; Bradford, Williams et al. 
1997; Cheshier, Morrison et al. 1999).  This finding implies that all HSCs in the BM 
contribute to steady-state hematopoiesis, thus arguing against an oligoclonal process. 
 
 The idea that the proliferative nature of HSCs may change during aging is 
consistent with the observation that the incidence of myeloproliferative disorders 
markedly increases with age in both mice and humans.  One study showing that the 
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frequency of HSCs in cycle in old B6 mice was three-fold higher than in young animals 
seems to corroborate this finding.  If true, this means that with a HSC frequency 7-fold 
higher in old mice, the increase in the absolute numbers of proliferating HSCs is quite 
profound (Morrison, Wandycz et al. 1996).   Furthermore, studies using serial 
administration of hydroxyurea or irradiation of BM cells have shown no evidence for a 
decline in the capacity of HSCs to proliferate. 
 
 It should come as no surprise that most factors responsible for regulation of the 
cell cycle were discovered in the study of cancer, a disease of dysregulated cellular 
proliferation.  A classic example is the retinoblastoma protein (pRb) that was first 
discovered as the affected gene product responsible for the development of retinal tumors 
during childhood.  It has since been shown that members of the pRb family act to 
suppress entry into active cell cycle and, upon their phosphorylation, allow for the 
assembly of the replicative machinery.  Their phosphorylation is governed by the 
concerted actions of the cyclin-dependent kinases (cdks) and the cdk inhibitors (ckis).  
Chief among the ckis are p16INK4a, p21cip-1 and p27kip-1.  Their role in hematopoietic 
progenitor cell proliferation was first shown by Mantel et al. (Mantel, Luo et al. 1996), 
who demonstrated that p21 levels rise while those of p27 decrease after stimulation by 
the hematopoietic cytokines Steel factor and G-CSF.  Additionally, it has been shown 
that p27 has no effect on proliferation of stem cells , yet has a dramatic anti-proliferative 
effect in progenitor cells (Cheng, Rodrigues et al. 2000).   It has also been shown that p21 
plays a role in both stem cell proliferation and self-renewal (Cheng, Rodrigues et al. 
2000).  Lewis et al. (Lewis, Chinswangwatanakul et al. 2001) demonstrated that mice 
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null for the p16INK4a locus exhibit increased proliferation in the progenitor compartment.  
It was recently shown that transcriptional repressors, such as the Gfi-1 gene product, 
promote HSC quiescence and thus maintain the HSC in its pluripotent state (Hock, 
Hamblen et al. 2004; Zeng, Yucel et al. 2004). While no studies have reported whether 
there are age-related alterations in the levels of these mitotic factors, it is tempting to 
hypothesize that these same molecular changes that contribute to tumorigenesis occur 
during ‘normal’ aging as well. 
 
DNA repair and genomic instability during aging  
 The fact that the HSC population must support hematopoiesis during the entire 
lifetime of the animal raises several interesting problems.  First, these long-lived cells are 
under constant stress from both endogenous and exogenous genotoxins that can have 
profound effects on their DNA.  Second, the proliferative nature of the HSCs and their 
immediate progeny makes them susceptible to DNA synthetic errors.  Third, any 
unrepaired lesions that occur in the cells’ DNA are necessarily passed on to their 
progeny.  This last statement implies that upon self-renewal of cells containing DNA 
lesions, these lesions will be fixed in the genome of the HSC pool.  To confront these 
potentially devastating processes, HSCs have been endowed with several defense 
mechanisms to ensure genomic stability (For review see (Park and Gerson 2005).  Murine 
HSCs preferentially express DNA repair genes compared to their mature progeny 
(Ivanova, Dimos et al. 2002; Ramalho-Santos, Yoon et al. 2002); however, human 
CD34+ cells have diverse responses to DNA damage with enhanced repair of UV-
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induced strand breaks, but impaired repair of nitrosourea-induced strand breaks 
(Myllyperkio and Vilpo 1999; Buschfort-Papewalis, Moritz et al. 2002).   
 
Fanconi anemia is a rare autosomal recessive genetic disease that results in hematopoietic 
failure in children and is composed of seven complementation groups.  When the Fanconi 
anemia group C (Fncc) gene was knocked out in mice, a significant decrease of 40 to 70 
percent of primitive HSCs was found with a corresponding increase in the sensitivity of 
these cells to the DNA damaging agent mitomycin C at two months of age.  This 
provides compelling evidence that DNA repair is an active process in HSCs and is critical 
for the maintenance of the HSC pool.  A similar effect on the hematopoietic compartment 
has been observed in mice expressing a hypomorphic allele of the double strand break 
repair gene RAD50, with complete BM failure occurring within 4 to 8 weeks of birth 
(Bender, Sikes et al. 2002). 
 
 While it is known that the ability of somatic cells to repair their DNA is altered 
during the aging process, evidence for this in HSCs is admittedly scant.  Most studies that 
imply a role for decreasing DNA repair ability of HSCs rely on gene knockouts that 
result in progeroid, or premature aging, phenotypes.  For instance, mice null for the repair 
protein Ercc1 show progressive marrow failure resulting in a pancytopenia, while the 
mice exhibit several symptoms of premature aging (Prasher, Lalai et al. 2005).  However, 
no studies to date have demonstrated conclusively that diminished DNA repair capacity 
of HSCs with age results in their functional impairment, much less a decreased ability to 
repair DNA lesions with age.    
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Genetic regulation of stem cell proliferation 
  
 These many ramifications of the proliferative nature of hematopoietic stem cells 
begs the question of what are the key molecules regulating this vital feature.  To be sure, 
the study of knockout and mutant mice as well as non-mammalian organisms has shed 
enormous light on how cells molecularly traverse the cell cycle.  However, these 
approaches are limited by the fact that i) gene knockouts and mutations are often 
influenced by compensatory pathways and ii) they do not reflect natural variation 
underlying complex traits.  To address these limitations, the field of quantitative genetics 
has embraced the use of inbred mice.  In fact, the study of inbred mouse strains has 
proven to be indispensable in the study of mammalian hematopoiesis, allowing for the 
definition of the hematopoietic hierarchy, molecular regulators of the various lineages, 
and theories of stem cell biology.  However, only recently has it been recognized that 
inbred mouse strains exhibit pronounced heterogeneity in various parameters of HSC 
function.  Indeed, our laboratory first became aware of this when it was observed that the 
fraction of spleen colony-forming units (CFU-S) in cycle markedly differed among 
various inbred mouse strains.  In particular we found a 10-fold difference in the fraction 
of these proliferating hematopoietic progenitor cells between the B6 and DBA/2J (D2) 
mouse strains, as assayed by a cell suicide technique (Van Zant, Eldridge et al. 1983).  
This extreme difference in cycling cells between the two strains could be due to extrinsic 
factors regulating cellular proliferation or intrinsic factors that were present within the 
cells.  To address this question, \chimeric (allophenic) mice were constructed by 
combining pre-implantation embryos from B6 and D2 mice and injecting them into 
pseudo-pregnant female mice.  In this way the extrinsic signals from the 
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microenvironment would be common to the HSCs of both mouse strains, while the cell-
autonomous differences would determine HSC function.  Blood cell chimerism studies 
were conducted for the duration of the individual allophenic lifetimes, which ranged from 
1.5 to 3 years.  In all animals tested, it was found that both D2 and B6 HSCs contributed 
to hematopoiesis as evidenced by the production of erythroid, lymphoid, and myeloid cell 
types during the first year of life.  Interestingly, during the second year of life, the 
contribution of the D2 HSCs to hematopoiesis began to decline, until at two years, blood 
cell production was wholly B6 in origin (Van Zant, Holland et al. 1990).  It most likely is 
not a coincidence that this time point is also near the natural lifespan of the D2 mouse 
strain.  In fact, as will be mentioned later, there is a striking correlation among various 
HSC parameters and organismal lifespan in the laboratory mouse.  With the observed 
differences in HSC cycling and hematopoiesis in chimeric mice, it is intriguing to invoke 
Hayflick’s theory of the limited replicative capacity of proliferating somatic cells.  In 
other words, did the D2 stem cell pool of chimeric mice reach its mitotic limit, thus 
allowing the slowly cycling B6 pool to take over blood cell production?  To answer this,  
BM from the allophenics in which D2 blood cell production had become undetectable 
was transplanted into myeloablated recipients and found that initially D2 HSCs once 
again contributed to hematopoiesis.  This, however, only lasted a few months, when once 
again blood cell production was solely of B6 origin.  This interval of D2 blood cell 
production was even shorter in secondary transplants, thus showing the presence and 
reversible quiescence of the D2 HSC population (Van Zant, Scott-Micus et al. 1992).  
Because some parameters of stem cell function were genetically regulated, we undertook 
genetic studies to identify molecular determinants of stem cell aging.   
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 The genetic studies that we have undertaken in this dissertation are based on the 
premise that strain specific differences in stem cell parameters are the result of unique 
combinations of genetic loci for which each mouse strain is homozygous.  To parse out 
the individual genes that are responsible for these phenotypes, it is necessary to generate 
mice that have unique combinations of genetic loci derived from the parental strains, in 
order that quantitative changes in stem cell function can be correlated to specific 
chromosomal loci.  In the context of our laboratory, we used the D2 and B6 mouse strains 
because of the strain-specific differences we have observed in HSC cycling and 
population dynamics with age.  Furthermore, a recombinant inbred (RI) line of mice 
derived from these two strains was already in existence and being utilized for quantitative 
trait studies.  The BXD RI mice consist of over 50 individual lines harboring unique 
homozygous combinations of B6 and D2 alleles.  The high density of markers that have 
been mapped in these strains (over 2000) allow for the mapping of quantitative trait loci 
(QTL) with a resolution of one centimorgan (cM).   
 
The CAFC assay:  High throughput identification of the hematopoietic heirarchy 
 This approach clearly would not have been possible using previously described 
methods due to the numbers of animals needed across the large number of BXD lines.  
Therefore, we applied a cell culture technique that relies on the survival, proliferation, 
and differentiation of HSCs in close association with a stromal cell monolayer.  The 
cobblestone area forming cell (CAFC) assay as initially described by Dexter and Lajtha 
(Dexter and Lajtha 1974) and further developed by Cashman and Ploemacher (Dexter 
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and Lajtha 1974; Cashman, Eaves et al. 1985; Ploemacher, van der Sluijs et al. 1991) is 
based on the observation that as HSC progeny transit the hematopoietic hierarchy, they 
expand in number and are increasingly in cycle (figure 1.1).  Limiting dilutions of BM 
cells are seeded onto FBMD-1 stromal cell monolayers in 96-well plates and assayed for 
the presence CAFCs at one-week intervals starting on day 7.  Indeed, the ‘primitiveness’ 
of the stem cell is highly correlated to its quiescent state, such that cells that form 
cobblestones on day 35 are more primitive and less numerous than those that form 
cobblestones on day 28 and so forth (Ploemacher, van der Sluijs et al. 1991).  
Furthermore, the cells that form CAFCs on day 35 are comparable to those able to initiate 
long term cultures as well as engraft irradiated recipients long term, and thus serve as a 
measure of stem cell activity in vitro (Breems, Blokland et al. 1994).   
 
 Initial studies reported that the frequency of day 7 CAFCs in cycle among eight 
inbred mouse strains using a hydroxyurea (HU)-suicide technique found that the percent 
of the HPCs in S-phase varied by more than 10-fold from the highest to lowest cycling 
strains as was seen previously using the CFU-S assay (figure 1.2).  Because it had 
previously been observed that this trait seemed to correlate to lifespan in at least the D2 
and B6 strains,  CAFC day 7 cycling data were plotted against the mean lifespan of the 
eight respective strains resulting in a striking inverse linear correlation of the two traits 
among all strains (de Haan, Nijhof et al. 1997).    The next step was to identify the 
genetic basis for this relationship by phenotyping each of the BXD lines for the day 7 
CAFC cycling trait to identify the responsible QTL.  As a result,  two major loci on 
chromosomes 7 and 11 and two minor QTL on chromosomes 4 and 9 were identified that 
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accounted for at least part of the cycling phenotype .  Using existing lifespan data of the 
existing BXD lines from Gelman et al. (Gelman, Watson et al. 1988), it was again found 
that a negative linear relationship between lifespan and HPC cycling exists.  Importantly, 
on mapping the lifespan trait in the BXD lines, linkage to the same markers on 
chromosomes 7 and 11 responsible for CAFC day 7 cycling were found in addition to 
markers on chromosomes 2 and 4 (de Haan and Van Zant 1999).  Assuming a common 
gene underlies both loci, this would suggest but not necessarily prove that HSC/HPC 
cycling could limit lifespan through a replicative senescence mechanism of aging.   
 
The cytostatic action of hydroxyurea 
 The use of HU as a measure of cell proliferation is based upon the idea that the 
synthesis of DNA in proliferating cells is reliant on a readily available pool of 
deoxyribonucleotides.  The enzyme responsible for their production, ribonucleotide 
reductase, catalyzes the reduction of ribonucleotides to deoxyribonucleotides (Larsson 
and Reichard 1966; Larsson and Reichard 1966).  Indeed, studies have shown that when 
this enzyme is inhibited by HU, DNA synthesis is reversibly interrupted (Rosenkranz, 
Garro et al. 1966; Elford 1968).  This interruption of DNA synthesis leads to cell cycle 
arrest over the short term but, if this delay endures, can lead to significant DNA damage 
and eventually cell death.  Indeed, studies relying on the incubation of cultured cells in 
the presence of HU have shown DNA repair inhibition that can also lead to DNA strand 
breakage (Ishii and Bender 1980; Frankfurt, Seckinger et al. 1993).  These events are 
certainly toxic to the cells,  but may not be reflective of what occurs in vivo where HU is 
cleared rapidly from the circulation.  Nevertheless, studies have shown that stalled 
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replication forks signal through cellular pathways that are also activated by DNA strand  
breakage (Cuadrado, Martinez-Pastor et al. 2006).   
 As a result of these findings, the clinical use of hydroxyurea has come under 
increased scrutiny.  While HU was first synthesized almost 140 years ago it wasn’t until 
the 1960’s that it entered clinical use as a treatment for myeloproliferative disorders,  
(Dresler and Stein 1869).   In particular, its cytotoxic activity against proliferating cells 
provided a quick and reliable means of reducing circulating and bone marrow blood cell 
counts resulting from chronic and acute myeloid leukemia.  More recently, the use of HU 
has been extended to other disorders such as polycythemia vera and thrombocythemia 
that are characterized by increased erythrocyte and platelet counts, respectively (Levine, 
Wadleigh et al. 2005). Its use in these scenarios, however, must be balanced against the 
risk of developing treatment-related neoplasms (Sterkers, Preudhomme et al. 1998; 
Finazzi and Barbui 2005).  This risk is thought to arise from prior or concurrent  
cytoreductive therapies the patients receive that also rely on the induction of DNA 
damage.  Hydroxyurea has been reported to inhibit DNA repair, so it is thought that this 
could promote the transformation of damaged cells (Snyder 1988).  This cause/effect 
relationship has rarely been observed in the clinic, but must still be considered when the 
physician is planning a course of treatment. 
 While HU is only one of many cytoreductive agents that are in use for 
myeloproliferative disorders, it is often the first choice of treatment for sickle cell 
anemia.  Sickle cell anemia is a disease where a mutation in hemoglobin causes the loss 
of membrane compliance of red blood cells.  As a result, the red blood cells become rigid 
and elongated, making it difficult to traverse the circulation at the level of the capillaries.  
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Hydroxyurea acts to increase the production of fetal hemoglobin (HbF), which acts to  
inhibit the polymerization of the sickle form of hemoglobin.  While the mechanism which 
brings about this response is unknown, it has been reported that HU may or may not have 
a leukemogenic potential related to its ability to induce interchromosomal recombination 
(Galli and Schiestl 1996).  Despite this controversy, the use of HU in the treatment of 
sickle cell anemia is likely to continue into the foreseeable future.  Thus, a greater 
understanding of its mechanism of action could potentially allow HU to play a more 
significant role in the clinic.            
   
Experimental goals and significance 
 The relationship between the sensitivity of HSC/HPCs to HU and lifespan in the 
B6 and D2 mouse strains implies a common genetic mechanism.  Understanding the gene 
or genes underlying these two traits would lead to a greater understanding of how 
lifespan is genetically determined.  Furthermore, the fact that HU is still of clinical 
interest, and that its tolerance and efficacy varies among patient populations, gives 
increased validity of understanding the mechanisms that regulate the sensitivity of HSCs 
and HPCs to its killing properties.  The goals of this research are thus to i) confirm the 
role of the chromosome 7 locus in the regulation of HSC/HPC killing by HU, ii) elucidate 
potential mechanisms affected by this locus, and iii) identify potential candidate genes 
that underlie the HU sensitivity trait of HSC/HPCs.   
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Figure 1.1  The relationship between the fraction of HSC/HPCs killed by HU and 
mean lifespan in eight inbred mouse strains.   
The fraction of day 7 CAFCs (HPCs) killed by HU was measured and plotted against 
mean lifespan for eight inbred mouse strains.  The significant inverse linear relationship 
suggests a correlation between cellular proliferation in HSC/HPCs and lifespan 
determination. 
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Figure 1.2  The hematopoietic hierarchy as defined by the CAFC assay.   
The CAFC assay operates on the premise that the hematopoietic cellular hierarchy is 
organized along a continuum of decreasing proliferative potential, clonogenicity, and 
pluripotency.  The HSC lies at the top of this developmental tree and is considered to 
harbor the major responsibility of hematopoiesis throughout the lifespan.  Its 
identification here is based upon its relative quiescence, such that it begins to proliferate 
after five weeks in culture.  Hematopoietic progenitor cells, on the other hand, are highly 
proliferative and so begin to proliferate between 1 and 3 weeks of cell culture.  This 
feature is evidenced by the formation of colonies whose morphology is reminiscent of a 
cobblestone.     
Copyright © Jeffrey L. Yates 2006 
 20 
 
CHAPTER TWO 
Mapping and confirmation of a QTL regulating the response of hematopoietic 
stem/progenitor cells to hydroxyurea 
Summary 
 The proliferative potential of hematopoietic stem and progenitor cells is tightly 
regulated during steady-state hematopoiesis.  Furthermore, a genetic basis for this control 
has been implicated by the finding that inbred mouse strains, especially the B6 and D2 
strains, vary in their fraction of cycling HSC/HPCs.  Employing a hydroxyurea-suicide 
assay to measure the fraction of progenitor cells in S phase of the BXD recombinant 
inbred lines, two major loci on chromosomes 7 and 11 were found to control for the trait.  
Here, we have generated congenic mice where a region of proximal chromosome 7 
harboring the quantitative trait locus (QTL) was crossed between the B6 and D2 mouse 
strains.   Initially, no difference in the killing of HSC/HPCs between the inbred and 
background mouse strains was found.  Using a marker-assisted backcross strategy, the 
congenic interval was refined to a 1.7 cM, or 6 megabase (Mb) length of proximal 
chromosome 7.  Phenotyping of these subcongenic mice confirm that when the low-
killing B6 allele is present on a D2 genetic background (D2.B6 chr. 7), the B6 HU-killing 
trait is imparted.  Similarly, the high-killing D2 trait is conveyed when the D2 allele is 
present on a B6 background (B6.D2 chr. 7).  Furthermore, the population of whole bone 
marrow, progenitor and stem cells does not differ between the D2 and D2.B6 chr. 7 
strains.  However, the frequency of HPCs is significantly higher in B6.D2 chr. 7 mice 
compared to that of B6 mice.  It is thus concluded that i) a locus on proximal 
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chromosome 7 regulates the fraction of proliferating cells in the bone marrow in both D2 
and B6 mice and ii) the B6 allele of this locus does not impact the cellularity of the 
mouse bone marrow. 
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Introduction 
  
 Understanding the mechanisms that underlie cellular proliferation is critical for 
developing novel therapies that can either promote or suppress entry into the cell cycle.  
While cell cycle induction would be of benefit in a bone marrow transplant setting, it is 
often the inhibition of excessively proliferative cells that is required in the clinic.  These 
myeloproliferative disorders, such as acute myeloid lymphoma and polycythemia vera, 
are often treated with agents that block entry into and progression through the S-phase of 
the cell cycle.  Hydroxyurea is one such drug that inhibits the enzyme ribonucleotide 
reductase, thus preventing the synthesis of nucleotide substrates for DNA synthesis.  
Hydroxyurea has also found favor with researchers as a means to i) synchronize cells in 
the G0/G1 phase of the cell cycle and ii) measure the fraction of S-phase cells in a cell-
suicide assay.  Indeed, one of the first reports of a genetic basis for HSC proliferation 
reported that the fraction of CFU-S killed by HU was much greater in the D2 and 
C3H/He mouse strains compared to B6 (Van Zant, Eldridge et al. 1983).  This spawned a 
large number of studies attempting to determine the basis for this strain difference in HU 
susceptibility.   
 With a relevant phenotype in hand, it is often prudent to use a forward genetics 
approach to identify the causative gene(s).  As a first step in this process, quantitative 
trait loci (QTL) must be identified that are linked to the phenotype of interest.  This is 
accomplished by performing trait analysis of a genetic reference population (GRP).  A 
GRP is defined by a collection of stable genotypes in random combinations derived from 
the parental strains.  One such population, the BXD recombinant inbred (RI) line, is 
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derived from the B6 and D2 mouse strains and now consists of 34 separate lines.  Figure 
2.1 shows a schematic of the breeding structure for deriving the BXD RI mice.  Breeding 
is initiated by mating a B6 and D2 mouse to produce an F1 generation.  The genomes of 
the F1s are completely heterozygous at each autosomal locus.  Genetic diversification 
occurs at this step as the result of meiotic recombination in the germ line.  F1 brother-
sister matings then produce an F2 generation with unique genomic profiles.  Pairs of F2 
brother-sister matings are then isolated and inbred for 20 generations to homozygosity.  
The result is an RI line that consists of individual strains that harbor unique allelic 
combinations.  These regions of B6 and D2-derived DNA are delineated by polymorphic  
microsatellite markers  for which each BXD strain has been typed.  The resulting strain 
distribution pattern (SDP) can thus be resolved to the centimorgan (cM) level, which is 
equivalent to roughly 2 Mbp in the mouse.  The next step in a mapping experiment is to 
phenotype each of the RI strains for the trait of interest to derive a phenotype distribution 
pattern (PDP).  The SDP and the PDP are then compared using a computer algorithm that 
determines the association between D2 or B6 alleles at each genomic region and the 
degree of phenotypic variation.  The result is a linkage map that rank orders the linked 
loci according to the likelihood ratio statistic (LRS).  This statistical measure is based 
upon a 5000 permutation test whereby the SDP is randomly redistributed to determine the 
frequency with which the linked loci are again found.  Thus, the LRS score is a fairly 
accurate measure of the linkage of a particular trait to a specific chromosomal region.  At 
this point, several options are available.  If the QTL region is small enough, a candidate 
gene approach can be undertaken.  This relies on hand-picking genes with an associated 
role in the phenotype of interest.  However, this relies on the assumption that there is a 
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manageable number of genes in the interval and that the annotation of gene function 
suggests a putative role in the phenotype.  A second option is the generation of mice that 
are congenic for the QTL-containing chromosomal region.  This process is  summarized 
in figure 2.2, where F1 mice are generated in a similar fashion to the construction of RI 
mice.  Next, F1 mice are then backcrossed to either the B6 or D2 parental strain to 
generationally dilute out the non-QTL harboring DNA.  This backcrossing approach is 
carried out for at least 10 generations to achieve >99% enrichment for the QTL interval.  
A final brother-sister mating brings the congenic region into homozygosity.  While this is 
a time-consuming and laborious process, a speed congenic approach can cut the time to 
reach similar  genomic enrichment in half.  This method relies on typing mice at each 
generation for the allelic distribution of microsatellite markers at every 10cM along the 
entire genome.  Mice with the greatest amount of parental DNA are then chosen for 
further backcrossing.  This approach has been further accelerated by the use of BXD RI 
strains as founders.   The greatest utility in this approach to QTL analysis is the fact that 
along the way to identifying the candidate gene, the mapping data can be confirmed.  
Furthermore, congenic strains serve as a platform for positional cloning.  The data in this 
chapter summarize the results of the generation of mice congenic for the chromosome 7 
QTL regulating the response of HSC/HPCs to HU as well as the confirmation of the 
QTL.                
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Materials and Methods 
 
Animals 
 Female DBA/2J and C57BL/6J mice, 6-10 weeks of age, were purchased from 
The Jackson Laboratory (Bar Harbor, ME, USA).  Mice were housed under specific 
pathogen free conditions at the University of Kentucky Division of Laboratory Animal 
Resources.  All animal experiments were approved by the Institutional Animal Use and 
Care Committee of the University of Kentucky. 
 
Generation of Congenic Mice 
Congenic mice were generated from previously existing congenic strains that contained a 
60 cM span of proximal chromosome 7 on both D2 and B6 backgrounds (Geiger, True et 
al. 2001).   This congenic interval contained 4 mapped QTL, one for HU-killing at 0.5 
cM and three controlling for HPC frequency in the bone marrow at 8, 25, and 50 cM.  
Initial phenotyping of these animals was not able to confirm the role of the chromosome 
7 locus in HU sensitivity of HSC/HPCs.  Thus, congenic mice were backcrossed a further 
four to five generations to isolate the HU-killing locus.  Specifically, male congenic mice 
were bred to either B6 or D2 females, the offspring of which were genotyped for the 
alleles of microsatellite markers between 0 and 60 cM.  This marker-assisted backcross 
strategy resulted in congenic mice with a consensus congenic interval of 1.7 cM. 
 
Bone marrow isolation 
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 Bone marrow aspirates were collected by flushing the femora and tibiae with ice-
cold Hank’s Buffered Saline Solution (HBSS) containing 2% FCS with a 3 cc syringe for 
all experiments (2mL/mouse).  
 
CAFC Assay 
 The CAFC assay is an in vitro culture assay used to determine the frequency of 
HSC/HPCs in the bone marrow. The FBMD-1 stromal cell line was cultured in the wells 
of a 96-well plate for 7-10 days, allowing the cells to form a confluent monolayer.  
Whole bone marrow aspirates in Iscove’s Modified Eagle Medium (IMDM) 
supplemented with 20% horse serum (Gibco), 10-4 M 2-Mercaptoethanol, 10-5 M 
hydrocortisone (Sigma, St. Louis, MO), 80 U/mL penicillin, and 80 mg/mL streptomycin 
are then layered over the stromal cells in three-fold dilutions from 333 to 81000 cells per 
well, 20 wells per dilution.  The presence of cobblestones, non-refractile colonies of >5 
cells, is then assayed at one week intervals starting at day 7 and continuing through day 
35.  CAFC frequencies were determined using maximum likelihood analysis.  For our 
experimental purposes, only CAFC day 7 frequencies were determined. 
 
QTL mapping 
 Quantitative trait locus mapping was performed using the web-based WebQTL 
program (http://www.genenetwork.org).  The fraction of day 7 CAFCs killed by HU in 
each of the 26 BXD RI strains was entered into the database.  Interval mapping was 
performed using both a bootstrapping algorithm along with a 5000 permutation test.  The 
result is a linkage map with statistically relevant loci defined by peak likelihood ratio 
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statistic (LRS) scores.  Marker regression was also performed to identify the 
microsatellite markers showing the tightest linkage to the phenotype.  
 
Assessment of CAFC day 7 killing by HU 
 Mice (3 per experimental group) were injected intraperitoneally (IP) with 250 uL 
of either saline or 2 mg/mL HU dissolved in saline.  One hour after injection, mice were 
sacrificed and the bone marrow flushed and from the femora with ice-cold Hank’s 
balanced salt solution (HBSS) supplemented with 2% fetal calf serum.  The CAFC assay 
was performed and at day 7 CAFC frequencies were determined for both saline- and HU-
treated bone marrow.  The percentage of cell killing was determined by subtracting the 
frequency of day 7 CAFC in HU-treated samples from that of saline-treated samples and 
dividing by the day 7 CAFC frequency of the saline-treated group.  A minimum of five 
biological replicates were performed for each strain. 
 
Statistical analysis 
  
 One way ANOVA was performed for the comparison of each congenic strain with  
its respective parental strain.  Significance was assessed with a cutoff value of P = 0.05. 
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Results 
 
Re-mapping of a QTL influencing the response of HSC/HPCs to HU 
 The fact that the first generation of chromosome 7 congenic mice did not differ in 
the frequency of HSC/HPCs killed by HU necessitated that the phenotype be re-mapped.  
To this end, a web-based mapping tool, WebQTL, was used to once again compare the 
PDP and SDP of the BXD RI line.  In agreement with the prior mapping data, two loci on 
chromosomes 7 and 11 were shown to regulate the response of HSC/HPCs to HU (figure 
2.3).  However, the minor loci on chromosomes 4 and 9 are no longer present.  
Furthermore, loci on chromosomes 2 and 7 were again shown to be involved in the 
regulation of lifespan of the B6 and D2 mouse strains (figure 2.4).  In fact, the 
chromosome 7 locus is the major locus influencing this trait, reaching a significant LRS 
score of 10.6.   
 
Generation of the subcongenic B6.D2 and D2.B6 chromosome 7 sub-congenic mice 
 Confirmation of the mapping data led us to initiate a backcrossing strategy to 
reduce the size of the congenic interval in an effort to obtain the HU-killing phenotype.  
As shown in figure 2.2, B6.D2 and D2.B6 chr.7 (0-60 cM) mice were mated to their 
respective parental strain for an additional 4-5 generations to reduce the 4-60 cM interval 
harboring the QTL regulating HSC/HPC frequencies.  The resulting sub-congenic mice 
contained an interval of 0-1.7 cM for the D2.B6 chr.7 and 4.0 cM for the B6.D2 chr.7 
mice (figure 2.5).  This is equivalent to 6.0 Mbp and 18.8 Mbp intervals, respectively, 
and represents less than 0.1% of the entire mouse genome. 
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Congenic mice confirm the role of a QTL on proximal chromosome 7 in 
determining the sensitivity of HSC/HPCs to HU 
 The use of congenic mice is a powerful tool to confirm that a particular 
chromosomal locus does influence a particular trait if the “phenotype follows the 
genotype.”  Given this fact we set out to determine the fraction of day 7 CAFCs killed by 
HU in mouse strains congenic for the chromosome 7 locus.  In figure 2.6, it is shown that 
11.2% vs. 35.8% of day 7 CAFCs are killed from B6 and D2, respectively (p = 0.03).  
Furthermore, we show that 38.1% vs. 7.0%  of the progenitor cells are killed in the 
B6.D2 and D2.B6 congenic strains (p = 0.05), supporting the key role of the chromosome 
7 locus in hematopoietic progenitor cell turnover.     
 
Bone marrow cellularity is unaffected by the B6 allele of the chromosome 7 QTL 
 To determine whether the HU-killing phenotype imparted by the chromosme 7 
QTL is reflective of the absolute numbers of HPCs killed, we determined both the bone 
marrow cellularity and frequencies of HSC/HPCs in the bone marrow of the congenic 
and parental mouse strains.  As shown in table 2.1, both congenic strains had bone 
marrow counts similar to their respective parental strains.  Furthermore, the frequencies 
of HSC/HPCs as measured by both CAFC day 7-forming ability and cell surface 
phenotype, did not differ between the D2 and D2.B6 chr. 7 mice (1.5 vs. 1.8% and 68.2 
vs 55.6% , respectively).  However, the frequency of LIN-Sca1-ckit+ HPCs was 
significantly higher in B6.D2 chr. 7 mice compared to B6 mice (0.7 vs 1.1 %, 
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respectively; p < 0.05).  Furthermore, this difference may be mirrored in the frequencies 
of day 7 CAFCs of the two strains where B6 have 53.0 and B6.D2 chr. 7 have 74.1 per 
105 BMCs (p = 0.07).   
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Discussion 
 
 The data presented in this chapter supports the mapping data linking a locus at 0.5 
cM to the determination of HU sensitivity of HSC/HPCs.  Using congenic mice where a 
region of proximal chromosome 7 was introgressed between D2 and B6 inbred mouse 
strains, we confirmed that the D2 and B6 alleles of the QTL conferred upon HSC/HPCs 
high and low sensitivity to HU, respectively.  While the fraction of B6 and D2 
HSC/HPCs killed by HU is in agreement with previous reports, it should be noted that the 
congenic mouse strains account for most if not all the variance of the HU sensitivity 
phenotype (de Haan and Van Zant 1999).  While it is expected that mapping experiments 
will only identify large-effect QTL, i.e. those accounting for >5% of the total variance, 
one other major QTL associated with HU killing of HSC/HPCs was also identified on 
chromosome 11.  The reasons for this apparent anomaly are two-fold.  The first reason 
lies within the methodology used for the QTL mapping.  In order to map a particular trait 
to a chromosomal region, a genetic reference set must be defined and phenotyped.  In our 
case, a recombinant inbred (RI) line that had been derived from the B6 and D2 mouse 
strains (BXD) was phenotyped for the HU killing trait.  At the time only 29 BXD lines 
were available and so represented a limited amount of genetic diversity contained within 
the B6 and D2 mouse strains.  Therefore, it is possible and indeed likely that the variance 
in HU killing of HSC/HPCs observed in the BXD lines is not truly reflective of the entire 
variance between the total of high and low killing alleles.  Secondly, it is possible that the 
genes underlying the chromosome 7 and chromosome 11 QTL lie within the same 
signaling cascade or protein complex.  The idea here is that the two QTL would act as a 
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genetic complementation group where the HU killing “defect” could be rescued by the 
presence of the B6 allele of either QTL.   
 Interpreting the results of the HU killing experiments as being reflective of 
cellular proliferation would suggest that the fraction of HSC/HPCs in the bone marrow 
may be greater in the D2 and B6.D2 chr.7 mouse strains.  In agreement with previous 
reports we found a significant difference in the frequency of LIN-Sca1-ckit+ HPCs 
between the two parental strains (Geiger, True et al. 2001).  Furthermore, it was found 
that the B6.D2 chr. 7 congenic mouse strain had a significantly greater frequency of LIN-
Sca1-ckit+ HPCs than its parental B6 strain, reflecting the relationship between the B6 
and D2 strains.  This seems to be supported by the fact that the B6.D2 chr. 7 mouse strain 
may also possess more day 7 CAFCs than the parental strain.  However, no difference in 
HPC numbers was found between the D2 and D2.B6 mouse strains.  These data are best 
explained by the difference in the congenic intervals harbored by the two congenic 
strains.  The B6.D2 chr. 7 interval is significantly longer than that of the D2.B6 chr. 7 
strain.  That no difference was found in HPC numbers in the latter strain would suggest 
that another gene in the B6.D2 chr.7 interval is influencing progenitor cell number.   In 
fact, the parental congenic strain from which these sub-congenic strains were derived, 
harbored a locus at 23Mbp that was linked to the regulation of HPC numbers in young 
mouse bone marrow.  Because of the lack of microsatellite markers between the 16 and 
23 Mbp loci, the linkage analysis was not able to discriminate where the actual break 
points between D2 and B6 alleles are positioned.  Therefore, it is possible that the B6.D2 
chr. 7 mouse harbors the gene that underlies the QTL for HPC frequency regulation.  We 
thus conclude that the consensus congenic interval spanning 1.7 cM of proximal 
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chromosome 7 regulates the response of HSC/HPCs to  HU, while affecting neither bone 
marrow cellularity nor frequencies of HSC/HPCs. 
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Figure 2.1  Generation of the BXD recombinant inbred (RI) line.   
These mice are a valuable tool for QTL mapping due to their unique profiles of B6 and 
D2 derived genomes.  Thus, phenotypes are able to be correlated with the presence or 
absence of specific B6 and D2 alleles along the entire genome.  The result is a linkage 
map detailing the chromosomal intervals that influence the mapped trait.
chr. 7 QTL 
Genotype at 
chr. 7 QTL 
BXD strain 
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Figure 2.2  Generation of the chromosome 7 congenic mice.   
Congenic mice harbor a region of chromosome 7 that has been moved between the D2 
and B6 mouse strains using a marker-assisted backcross strategy.  By selecting for 
offspring that harbor the QTL-containing interval with the greatest amount of parental 
DNA, the congenic interval can be obtained in as few as 5 generations.   
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Figure 2.3  QTL mapping of day 7 CAFC killed by HU.   
A genome-wide linkage analysis revealed loci on chromosomes 7 and 11 that reached a 
suggestive LRS score of 9.8.  The x-axis represents increasing distance along each 
chromosome (indicated along the top of the figure) from centromere to telomere (as 
measured by microsatellite markers along the bottom of the figure).  The black line 
represents LRS scores along the chromosomes while gray lines indicate additive effects.  
Additive effects above the baseline represent regions of the chromosome where D2 
alleles increase the trait, i.e. higher HU killing, while a negative value indicates B6 alleles 
increase the trait.  As shown, positive additive effects are coincident with the suggestive 
loci.    
Suggestive 
threshold 
Chr. 7 QTL 
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Figure 2.4  QTL mapping of lifespan.   
A genome-wide linkage analysis revealed loci on chromosomes 2 and 7 that reached a 
suggestive LRS score of 10.6.  The x-axis represents increasing distance along each 
chromosome (indicated along the top of the figure) from centromere to telomere (as 
measured by microsatellite markers along the bottom of the figure).  The black line 
represents LRS scores along the chromosomes while gray lines indicate additive effects.  
Additive effects above the baseline represent regions of the chromosome where D2 
alleles increase the trait, i.e. higher HU killing, while a negative value indicates B6 alleles 
increase the trait.  As shown, negative additive effects are coincident with the 
chromosome 7 locus, indicating that B6 alleles increase the trait.   
Suggestive 
threshold 
Chr. 7 QTL 
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Figure 2.5  Genotype of the D2.B6 chr. 7 congenic mice.   
Microsatellite (Mit) markers are regions of polynucleotide repeats in the genome whose 
length varies in a strain-specific pattern.  In this case, the Mit markers D7Mit178, 
D7Mit340, D7Mit75, and D7Mit190 are polymorphic between the D2 and B6 strains as 
shown by the PCR bands of the control B6, D2 and B6.D2 F1 DNA.  While only markers 
corresponding to 3, 4, 6, and 14 Mbp of chromosome 7 are shown, the remainder of the 
chromosome was genotyped at 20 Mbp intervals.  This gel image confirms that the length 
of the congenic interval is confined to the first 6.1 Mbp of chromosome 7.
D7Mit178 
 
D7Mit340 D7Mit75 D7Mit190 
D
2.
B6
 c
hr
. 7
 
B6
 
D
2 
B6
.D
2 
F1
 
3.4 Mbp 4.2 Mbp 6.1 Mbp 16.2 Mbp 
 39 
Table  2.1  Bone marrow cell fractions in the congenic and parental mouse strains 
Strain WBM (x106) LIN- 
LIN-S-K+ 
(HPC) 
LIN-S+K+ 
(HSC) 
Day 7 CAFC 
(per 105 
BMCs) 
B6 17.0±2.0 1.6±0.1 0.7±0.1 0.08±0.04 53.0 ± 6.7 
B6.D2 
chr.7 17.0±1.2 2.3±0.3 1.1±0.1
* 0.10±0.02 74.1 ± 5.6# 
D2 10.6±1.1 2.8±0.1 1.5±0.2 0.15±0.01 68.2 ± 12.0 
D2.B6 
chr.7 10.3±1.2 2.7±0.1 1.8±0.04 0.12±0.02 55.6 ± 5.2 
 
Statistical comparisons between parental and congenic strains determined from minimum 
of seven independent groups of three mice each.   
Values are expressed as mean % ± standard error of the mean (SEM), except for WBM 
and day 7 CAFC as noted in table. 
* Indicates p < 0.05 for B6 vs. B6.D2 chr.7 comparison. 
# Indicates p = .07 
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Figure 2.6  Frequency of day 7 CAFC killed by HU in chromosome 7 congenic and 
parental mice.   
Percent killing was calculated as (# day 7 CAFC (saline) - # day 7 CAFC (HU) / # day 7 
CAFC (saline)) * 100 and is expressed as % ± SEM.  Data is compiled from a minimum 
of five independent pools of 3 mice each.  Statistical comparisons were made using one-
way ANOVA between B6:B6.D2 chr. 7 (*p = 0.03) and D2:D2.B6 chr. 7 (#p=0.05). 
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CHAPTER THREE 
Investigation into the mechanisms underlying the strain-specific response of 
hematopoietic stem/progenitor cells to hydroxyurea 
Summary 
 In order to confirm that the HU sensitivity phenotype is due to a difference in the 
frequency of cycling stem and progenitor cells in the bone marrow, we measured steady-
state cell cycling by injecting mice with the thymidine analogue BrdU and calculating the 
fraction of BrdU incorporating cells.  We first found that there is no difference in the 
frequency of cycling whole bone marrow cells between the inbred strains and their 
respective congenic strains.  Surprisingly, we have also found similar frequencies of 
proliferating cells in the progenitor and stem cell compartments.  Ensuing studies were  
directed at identifying potential mechanisms for the differing HU sensitivities of the B6 
and D2 mouse strains.  We first determined the time course over which HU was 
inhibiting cell cycle progression in whole bone marrow.  Over the course of 24 hours 
after HU administration, we found that DNA synthesis is inhibited for between 3 and 3.5 
hours in B6 and D2 mice.  At this time, cell cycle progression began in both strains and 
fully recovered by 6 hours.  However, while cell cycle re-entry occurred solely from 
G0/G1 cells in D2 BM, B6 cells in S/G2/M phase survived the cell cycle inhibition and 
began incorporating BrdU.  Next, we analyzed the proliferative response of B6 and 
B6.D2 chr. 7 mice after bone marrow transplantation and found that whole bone marrow 
(WMB) from B6.D2. chr. 7 has a proliferative advantage at 72 hours after transplant.  
Finally, we studied the frequency and duration of HU-induced DNA damage by 
measuring the phosphorylation of the histone variant, H2AX over a time course 
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coincident with cell cycle inhibition and restart.  Our results show that i) only S-phase 
cells display phosphorylated H2AX after HU treatment, ii) the time course for 
phosphorylation/dephosphorylation of H2AX does not differ between B6 and D2 bone 
marrow, and iii) the amount of phosphorylated H2AX is greater in B6 than D2 BM.  We 
conclude that i) the difference in sensitivity of HSC/HPCs to HU is independent of their 
cycling status, ii) a portion of BMCs from B6 mice survive HU to re-enter cell cycle, 
while those of D2 do not, iii) the D2 allele of the congenic interval imparts a proliferative 
advantage after transplant, and iv) B6 and D2 WBM do not differ in the amount and 
repair of DNA damage following HU treatment.  
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Introduction 
 
 Hematopoietic stem and progenitor cells (HSC/HPCs) are under considerable 
proliferative and genomic stress, having to constantly replenish an aging blood cell pool 
while sustaining a variety of genomic lesions with every cell division due to the inherent 
error rate of DNA synthesis.  Indeed, it is when these processes go awry that the 
development of cancer and organismal aging are set into motion.  Importantly, HU is well 
suited to study these processes in proliferating cells given the fact that it is both a 
genotoxin and a pro-proliferative agent.  However, its actions in vivo have not been well 
defined.  It is known that some of the initial signaling molecules are members of the 
ATM/ATR phosphoinositol-3 kinase family, which act to phosphorylate various 
downstream effectors such as Chk1, p53, and the recently discovered histone variant 
H2AX (Celeste, Fernandez-Capetillo et al. 2003; Alderton, Joenje et al. 2004).  While 
chk1 and p53 act to amplify the damage signal and thus determine whether the cell will 
survive or apoptose, histone H2AX phosphorylation is thought to allow for the opening 
of the chromatin structure in the vicinity of stalled repliction forks, thus allowing for 
access to repair factors (Paull, Rogakou et al. 2000; Celeste, Fernandez-Capetillo et al. 
2003).  Significantly, HU has conclusively been shown to induce the phosphorylation of 
histone H2AX (referred henceforth to  gamma-H2AX) in proliferating cells (Ward and 
Chen 2001; Kurose, Tanaka et al. 2006).   
 The mechanisms that act to signal HSC/HPC  to enter the cell cycle have not been 
well defined.  As mentioned in chapter one, a variety of cyclins and cyclin-dependent 
kinases have been shown to regulate the quiescence and proliferation of HSC/HPCs when 
their expression is perturbed.  However, it is not known how these molecules are 
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regulated during steady-state hematopoiesis.  A more accurate picture of how the cell 
cycle is regulated perhaps comes from studies involving conditions that favor cell 
proliferation, such as cell injury.  This can be accomplished in the bone marrow using 
myeloablative treatments such as ionizing radiation or HU.  For instance it has been 
reported that within the first 12 hours of recovery after HU treatment as many as 60-65% 
of the HSC/HPCs enter the active cell cycle (Necas and Cinatl 1982).   This observation 
is similar to that observed 12 hours after bone marrow transplantation in mice, where it 
has been reported that over half of the donor bone marrow cells are in S phase (Nilsson, 
Dooner et al. 1997).     
 While much is known about the cellular processes that are affected by HU, the 
metabolic fate of HU remains a mystery for the most part.  What is known is that the 
half-life of HU in plasma is on the order of 10-20 minutes, and this seems to be 
conserved across species.  These studies have also reported that the majority of HU is 
excreted with no modification in the urine.  (Van den Berg, McGill et al. 1994; Iyamu, 
Lian et al. 2001).  However, it has been shown that HU is concentrated within 
lymphocytes for up to two hours after HU administration (Rosner, Rubin et al. 1971).   
Thus, these studies indicate a rapid course of action of HU with an equally rapid recovery 
and that this can vary markedly according to tissue type. 
 In this study, we investigated whether the chromosome 7 congenic interval 
regulates steady state and HU-induced cell cycle progression of HSC/HPCs.   
Furthermore, we have defined the proliferative response of WBM and HPCs after bone 
marrow transplantation in both B6 and B6.D2 chr. 7 mice.  Finally, we have investigated 
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the DNA damage potential of HU in the bone marrow by assessing histone H2AX 
phosphorylation.    
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Materials and Methods 
 
Animals 
 Female DBA/2J and C57BL/6J mice, 6-10 weeks of age, were purchased from 
The Jackson Laboratory (Bar Harbor, ME, USA).  Mice were housed under specific 
pathogen free conditions at the University of Kentucky Division of Laboratory Animal 
Resources.  All animal experiments were approved by the Institutional Animal Use and 
Care Committee of the University of Kentucky.   
   
Bone marrow isolation 
 Bone marrow aspirates were collected as described in chapter one. 
       
Measurement of cycling fraction of bone marrow cells 
 Mice were injected intra-peritoneally (IP) with either saline or hydroxyurea (2 
mg/g body weight ; Sigma).  At 1, 3, and 4 hours after HU injection, 50 mg of BrdU 
(Sigma) in 250 uL phosphate buffered saline (PBS) was injected IP.  After 30 minutes, 
mice were sacrificed and marrow collected as stated previously.  An aliquot of 1x106 cells 
was set aside for the cycling determination of unfractionated whole bone marrow.  The 
remaining marrow samples were layered onto Ficoll and centrifuged at 1700 rpm for 30 
minutes at 18oC.  After centrifugation, the mononuclear cell-containing buffy coat was 
aspirated, washed twice with media and stained with the following antibodies:  
biotinylated lineage cocktail (Mac-1 (macrophages), Gr-1 (granulocytes), TER-119 
(erythroid), CD5 (lymphocytes), CD8a (T-cells), and B220 (B-cells)), Sca-1, and c-Kit 
(all from BD Pharmingen, San Diego, CA, USA).   Cells were then fixed and 
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permeabilized with Cytofix/Cytoperm buffer for 30 minutes and washed with Perm/Wash 
buffer (BD Pharmingen).  Samples were then labeled with anti-BrdU (1 uL in 50 uL of 
Perm/Wash buffer; BD) for 30 minutes at room temperature and 7-Amino-actinomycin D 
(7-AAD; BD).  Cells were then analyzed on a Becton Dickinson FACS Vantage flow 
cytometer.   
   
Measurement of gamma-H2AX response to HU 
 Mice were injected intra-peritoneally with 50mg BrdU for 30 minutes prior to 
injection of 2mg/g hydroxyurea (HU).  Animals were then sacrificed at 0.5, 1,  3, and 4 
hours after HU administration, followed by cell isolation, fixation and staining as 
described above.  Finally, cells were labeled with anti-gamma H2AX (Upstate 
Biotechnology) diluted 1:100 in Perm/Wash buffer for 30 minutes at room temperature 
prior to FACS analysis. 
 
Competitive repopulation of bone marrow cells 
 Bone marrow cells were isolated from B6.D2 chr. 7 and B6 mice and injected into 
lethally irradiated recipient B6 mice at a dose of 2.5 x 106/mouse.  The discrimination of 
bone marrow cells from the two strains is accomplished by the detection of the Ly-5 cell 
surface marker.  The B6.D2 chr. 7 mice express the Ly-5.2 allelic variant, while the B6 
mice express the Ly-5.1 variant.  At 24, 48, and 72 hours after bone marrow injection, 
bone marrow was harvested, fixed, and stained with antibodies against Ly-5.1, Ly5.2, and 
BrdU.  The fraction of BrdU positive cells was then determined for the Ly-5.1 and 5.2 
fractions.   
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Statistical analysis 
 All statistical comparisons performed on a minimum of three replicate groups.   
Pair-wise comparisons were made with respect to each congenic and parental strain pair.  
One-way ANOVA (student’s t-test) were performed with a significance cutoff of p < 
0.05. 
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Results 
 
Measurement of the proliferating fraction of various BM subsets at steady state in 
inbred and congenic mouse strains 
 To confirm that the progenitor cell fractions of the background and congenic 
strains do indeed differ in the percentage of cells in S phase, we performed in vivo BrdU 
analysis of the progenitor and stem cells as defined by their surface phenotypes of LIN-
Sca1-ckit+ and LIN-Sca1+ckit+, respectively (figure 3.1).  We show here that there is no 
significant difference in the fraction of BrdU-incorporating cells among any of the bone 
marrow cell subsets between the background and respective congenic strains, thus 
showing that there is no difference in the proportion of cells in cycle (figures 3.2, 3.3, and 
3.4). 
 
Determination of the proliferative response in WBM after HU administration 
 The ability of cells to withstand the cytotoxic effects of HU could arise from a 
variety of mechanisms,  including the cell’s ability to metabolize the drug, or to withstand 
the cytotoxic effects of the drug,  Here, we have investigated these possibilities by first 
defining the time course over which HU is able to blockDNA synthesis.  We first found 
that DNA synthesis is inhibited immediately after the administration of HU and persists 
for three hours in both B6 and D2 bone marrow cells (figure 3.5).  We can thus conclude 
from this observation that the efficacy of the drug is equivalent in the two mouse strains.  
These data are consistent with the idea that both strains metabolize HU at similar rates.  
At roughly three hours after HU injection, bone marrow cells surviving the HU treatment 
began synthesizing DNA.  Consequently, BrdU incorporation in D2 bone marrow cells 
 50 
solely arose from the G0/G2 population, consistent with its use as a cell cycle 
synchronization agent.  However, bone marrow cells of B6 that had been in S-phase prior 
to HU, survived the cell cycle arrest and re-entered the cell cycle (arrow in figure 3.5).  
These data further support the notion that B6 bone marrow cells have a greater ability 
than those of D2 to withstand the cytotoxic effects of HU.  However, this phenotype was 
not observed in either the HSC/HPC population, nor in WBM of the D2.B6 chr. 7 mice 
(data not shown).  Thus, the ability of bone marrow from B6 mice to survive HU-induced 
cell cycle arrest is not regulated by the chromosome 7 congenic interval. 
      
Determination of the proliferative response in WBM and HPCs after bone marrow 
transplantation 
 Previous studies have shown that the proliferative response of bone marrow cells 
in D2 mice is significantly greater than that observed in B6 mice after myeloablation with 
5-fluorouracil.  In order to determine whether this phenotype is a consequence of the 
chromosome 7 QTL, we transplanted equal numbers of bone marrow cells from B6 and 
B6.D2 chr. 7 congenic mice into lethally irradiated hosts.  At 24, 48, and 72 hours after 
transplant, we injected the mice with BrdU and assessed the proliferating fraction of 
WBM and HPCs.  In table 3.1, we show that the frequency of proliferating HPCs is not 
significantly different between the two populations at any of the three time points.  
However, in WBM we see that the fraction of proliferating B6.D2 chr. 7 BMCs is 
significantly higher than those from B6 at 72 hours after transplant (8.6 vs. 3.3, p=0.02). 
 
Analysis of gamma-H2AX phosphorylation in WBM after exposure to HU 
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 In an effort to assess the DNA damage response of the bone marrow cells to HU, 
we assayed the phosphorylation status of the histone variant H2AX before and after HU 
injection.  This histone becomes phosphorylated in the vicinity of stalled replication forks 
and DNA double strand breaks.  We first confirmed that HU targets only cycling cells by 
treating BrdU-labeled LIN- bone marrow cells with HU.  As can be seen in figure 3.7, 
H2AX phosphorylation occurs within 5 minutes of HU treatment, in parallel with the 
effects of HU upon cell cycle progression.  This effect plateaus within one hour and is 
significantly decreased by 3 hours.  Furthermore, this time course of H2AX 
phosphorylation does not differ between B6 and D2 mice.  As it has been shown that the 
amount of phosphorylated H2AX is proportional to the number of DNA lesions, we 
measured the mean fluorescence intensity (MFI) of gamma-H2AX at each of the time 
points.  The data shown in figure 3.8, indicates that B6 LIN- cells have more 
phosphorylated H2AX than D2 LIN- cells at three and four hours after HU 
administration.   
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Discussion 
   
 In this series of experiments we found that the frequency of BrdU-incorporating 
cells in the whole bone marrow, progenitor, and stem cell compartments does not differ 
between the inbred strains, nor their reciprocal congenic strains.  The rationale here being 
that the differing sensitivities to HU between B6 and D2 HSC/HPCs is reflective of 
unique proliferative properties.  This difference in the cycling fraction of B6 and D2 
HPCs is believed to be manifested during steady-state hematopoiesis such that by the 
time the bone marrow cells are layered onto the stromal cell layer one-hour after HU 
injection, the HU-sensitive cells would either be dead or in the process of dying.  Thus, 
the fraction of cells killed by HU would be an indirect measure of the fraction of 
proliferating progenitor cells in the bone marrow.  The fact that BrdU labeling did not 
confirm this hypothesis would suggest that the response of HSC/HPCs to HU is uniquely 
regulated in the two strains.  This could arise from either differences in the metabolism of 
HU or in the response to the resulting DNA damage.  To address these possibilities we 
defined the time course of HSC/HPC cell cycle arrest after HU injection in B6 and D2 
mice, as well as the congenic strains.   
 While the exact mechanism of HU metabolism is not known in detail, inferences 
regarding its biological activity can be determined through time course measurements of 
S-phase arrest.  Within five minutes of HU injection all DNA synthesis in hematopoietic 
cells is inhibited and persists for 3 hours.  This is in agreement with other studies 
comparing HU-induced cell cycle arrest both in vitro and in vivo (Necas and Hauser 
1982; Woo, Bak et al. 2005).   DNA synthesis recovers in both BMCs of B6 and D2 mice 
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between 3 and 4 hours, indicative of similar clearance of HU between the two strains.  
However, it was found that B6 cells in S phase at the time of HU treatment survive and 
re-enter the cell cycle while those of D2 do not.  This striking observation confirms the 
results of a report using ICR mice that CFU-S in the middle of S phase are resistant to the 
cytotoxic effects of HU, while those CFU-S in early and late S phase are maximally 
sensitive to HU.  Thus, they found that only 80% of S phase cells are killed by HU 
(Necas and Hauser 1982).  This finding supports the idea that B6 BMCs in S phase are 
less sensitive to the cytotoxic effects of HU.  However, when BMCs of D2.B6 chr. 7 
mice were analyzed in this way, the pattern of BrdU incorporation recapitulated that seen 
in D2 BMCs.  Thus, this trait is not regulated by the presence of B6 alleles of proximal 
chromosome 7.  Next, we analyzed HPC/HSCs in the bone marrow of B6 and D2 mice 
for this trait and likewise found that BrdU incorporation restarted only in the G0/G1 cell 
cycle compartment.  These data thus show that while D2 and B6 BMCs apparently 
metabolize HU efficiently, those of B6 are more resistant to the cytotoxic effects of HU.  
Furthermore, this trait is not controlled for by the chromosome 7 congenic interval, nor is 
the trait present in primitive HSC/HPCs.   
 Having shown that BMCs of B6 and D2 mice recover from HU over a similar 
time period, we next tested whether the proliferative response of the bone marrow is 
regulated by the chromosome 7 QTL.  These studies were inspired by the reports that the 
D2 mouse strain has a higher proliferative response than B6 after treatment with the 
thymidine synthase inhibitor, 5-fluorouracil (Phillips, Reinhart et al. 1992).  While our 
study did not investigate proliferation at the reported maximal time point of 12 hours, our 
findings suggest that the proliferative advantage may depend, in part, on time points other 
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than 12 hours.  The fact that WBM of B6.D2 chr. 7 mice has a proliferative advantage at 
72, but not 24 and 48 hours after transplant seems to support this prediction.  However, 
the fact that no difference was observed in the HPC compartment at any time point, 
suggests that another population in the bone marrow may be responsible for the 
difference in cycling kinetics after bone marrow transplantation.   
 Finally, we assessed whether the DNA damage response differs between the two 
strains.  Here, we have assayed for the presence of the DNA damage marker gamma-
H2AX.  Gamma-H2AX is a histone variant that is phosphorylated in the vicinity of 
stalled replication forks and DNA double-strand breaks (DSBs) (Rogakou, Pilch et al. 
1998).  This phosphorylation is a rapid event, occurring within 1 minute of the insult 
(Rogakou, Boon et al. 1999).  Furthermore, it has been shown that the amount of gamma-
H2AX is directly proportional to the number of DSBs present in the nucleus 
(Sedelnikova, Rogakou et al. 2002).  By defining the time course of the appearance and 
disappearance of gamma-H2AX, we can approximate the rates of damage induction and 
repair (Redon, Pilch et al. 2002). First, we confirmed that only S-phase cells of the bone 
marrow are targeted by HU by showing that only BrdU-labeled cells stained positive for 
the anti-H2AX antibody after HU treatment.  Next, we found that peak H2AX 
phosphorylation occurs within 1 hour of HU injection and decreases to 50% of the 
maximum by 3 hours.  Thus, H2AX dephosphorylation coincides with replication restart  
3 hours after HU administration.  Furthermore, we have shown that neither the time 
course of H2AX phosphorylation nor the frequency of cells positive for H2AX 
phosphorylation differs between the two strains.  Because the amount of gamma-H2AX 
in the nuclei is proportional to the number of strand breaks/stalled forks, we measured the 
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absolute amount of H2AX on a per cell basis.  Surprisingly, we show that the DNA of B6 
BMCs have a greater amount of phosphorylated H2AX than those of D2.  This result 
would seem to lie in contrast with the hypothesis that B6 are less sensitive to the effects 
of HU.  However, given that fewer B6 HSC/HPCs are killed than those of D2 mice, this 
finding reinforces the idea that B6 cells are able to sustain a greater amount of damage 
than D2 cells before activating a cell death program.   
 Our findings in this chapter thus call into question the exact biological process 
that HU is targeting.  While the fraction of cell killing by HU is not reflected in the 
fraction of BrdU-incorporating cells of the bone marrow, our finding that the D2 allele of 
the chromosome 7 interval imparts a proliferative advantage suggests that the underlying 
mechanism lies within the cell cycle regulatory machinery.  Further studies will need to 
be performed to determine the cell cycle regulators affected by the congenic interval. 
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Figure 3.1  BrdU and 7-AAD labeling of bone marrow.   
BrdU is a thymidine analogue that is incorporated into DNA undergoing synthesis.  
When the BrdU staining profile of bone marrow cells is plotted against total DNA 
content (7-AAD), each phase of the cell cycle is able to be defined.  Thus, it is possible to 
follow the progression of cells through the entire cycle. 
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Figure 3.2  Fraction of BrdU positive cells in whole bone marrow of congenic and 
parental strains.   
Values are expressed as % ± SEM and are derived from 3 independent samples of 3 mice 
each.  One-way ANOVA was performed on B6 vs. B6.D2 chr. 7 and D2 vs. D2.B6 chr. 7 
(all p > 0.05)
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Figure 3.3  Fraction of BrdU positive cells in the LIN-Sca1-ckit+ HPC fraction of 
congenic and parental strains.   
Values are expressed as % ± SEM and are derived from 3 independent samples of 3 mice 
each.  One-way ANOVA was performed on B6 vs. B6.D2 chr. 7 and D2 vs. D2.B6 chr. 7 
(all p > 0.05) 
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Figure 3.4  Fraction of BrdU positive cells in the LIN-Sca1+ckit+ HSC fraction of 
congenic and parental strains.   
Values are expressed as % ± SEM and are derived from 3 independent samples of 3 mice 
each.  One-way ANOVA was performed on B6 vs. B6.D2 chr. 7 and D2 vs. D2.B6 chr. 7 
(all p > 0.05)  
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Figure 3.5  BrdU incorporation of whole bone marrow after administration of HU.  
Flow cytometry plots show the time course of replication re-start 3 and 4 hours after HU 
injection.  Arrow indicates population of S phase cells that survive the HU treatment.
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4 hr post HU 
Control 
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Figure 3.6 Flow cytometry plots showing the phosphorylation of H2AX after HU 
treatment.   
A representative flow cytometry dot plot detailing the phosphorylation of the histone 
H2AX in the bone marrow of D2 mice.  Cycling cells are indicated by BrdU staining in 
upper left and right quadrants.  Gamma H2AX staining is reflected in the upper and lower 
right quadrants.  Note that only cells in S-phase contain gamma H2AX (upper right 
quadrant) at 30’ after HU.
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Figure 3.7  Time course of H2AX phosphorylation in bone marrow after HU 
treatment.   
Frequency of H2AX-positive cells within the BrdU-positive fraction indicates the 
phosphorylation of H2AX in the cycling fraction of bone marrow cells.  Values are 
expressed as mean ± SEM derived from 3 independent experiments of 3 mice for each 
strain.  All p-values > 0.05.
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Figure 3.8  Quantification of phosphorylated H2AX in bone marrow cells after HU 
treatment.   
Mean fluorescence intensity reflects the amount of epitope bound by the anti-H2AX 
antibody.  Values are expressed as mean ± SEM derived from 3 independent experiments 
of 3 mice for each strain.  All p-values > 0.05. 
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Table 3.1  Proliferative response of WBM and HPCs between B6 and B6.D2 chr. 7 
at 24, 48, and 72 hours after competitive transplantation 
 
WBM 24 hours  48 hours 72 hours 
B6 (5.1) 10.2 ± 2.2 3.05 ± 0.5 3.3 ± 0.6 
C.1 (5.2) 7.35 ± 0.7 6.45 ± 1.3 8.6 ± 0.5* 
LIN-Sca1-ckit+ 
HPCs    
B6 (5.1) 4.2 ± 0.7 7.6 ± 0.4 9.0 ± 1.7 
C.1 (5.2) 5.1 ± 0.8 8.3 ± 0.4 11.7 ± 1.5 
 
Percentages expressed as mean ± SEM from 2 experiments.   
At each time point, 3 recipient mice were sacrificed and the bone marrow pooled for 
BrdU analysis. 
* p = 0.02 B6 vs. B6.D2 chr. 7 WBM 
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CHAPTER FOUR 
Analysis of the genomic and proteomic profiles generated by a QTL regulating the 
response of hematopoietic stem/progenitor cells to hydroxyurea 
 
Summary 
 
 In an effort to identify the gene or genes underlying the chromosome 7 QTL at 0.5 
cM, we have performed whole genome microarray studies of HPCs in the two inbred and 
two congenic strains of mice.  In parallel, we have also profiled the cytoplasmic and 
nuclear proteomes of HPC-enriched bone marrow-mononuclear cells (BM-MNCs) 
through the use of 2-dimensional polyacrylamide gel electrophoresis (2D PAGE).  In a 
comparison of gene expression of B6 vs. B6.D2 chr.7 and D2 vs. D2.B6 LIN-Sca1-ckit+ 
progenitor cells, we have found that only 5 genes in the consensus congenic interval are 
differentially expressed.  Using quantitative RT-PCR, only Ndufa3 could be confirmed as 
being truly differentially expressed between the background strains and their respective 
congenic strain.  In order to more completely characterize the molecular basis of the HU-
killing trait, we isolated cytoplasmic and nuclear protein fractions from bone marrow 
mononuclear cells and subjected them to 2D-PAGE.  We have found that only eight 
cytoplasmic proteins are overexpressed in D2 compared to D2.B6 chr. 7 BM-MNCs.  
Furthermore, we could not detect any nuclear proteins that are overexpressed in D2 BM-
MNCs in comparison to those of D2.B6 chr. 7.  These results are in stark contrast to the 
numbers of proteins that are overexpressed in the cytoplasmic and nuclear fractions of the 
D2.B6 chr. 7 BM-MNCs (>200).  We are able to conclude from our results that the 
expression of only one gene in the congenic interval is regulated differentially by the B6 
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and D2 alleles of the chromosome 7 QTL.  Furthermore, we conclude that the 
chromosome 7 congenic interval exerts a profound gene activation effect when 
transferred to a foreign genetic background.  
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Introduction 
 
 The ultimate goal of quantitative genetics is to identify genes that underlie 
particular complex traits.  However, given the polygenic nature of these traits, it has been 
difficult to identify the underlying genes using traditional whole genome analyses.  
Traditional approaches have often relied on positional cloning, whereby the mapped 
interval is progressively refined to single gene resolution while preserving the phenotype 
of interest (Flaherty, Herron et al. 2005).  However, a large number of recombinational 
events must be scored at each generation, thus making the approach both costly and time-
consuming.  Often, this approach can be abridged by the use of congenic strains, where 
the mapped interval is narrowed to a manageable number of genes.  This can then be 
followed by a candidate gene approach, which involves handpicking genes on the basis of 
their known function and testing their effects upon the phenotype.  But how do genes 
exert their phenotypic influence?  The crux of this issue is that polymorphisms within the 
DNA sequence itself can alter gene expression, protein sequence, splice isoforms, and 
even post-translational modifications.  Furthermore, the discovery that gene and protein 
expression can also be influenced by chromatin modification and microRNAs, provides 
further mechanistic possibilities for complex traits.  Attempting to explain complex traits 
by any one of these mechanisms would be a difficult endeavor if starting only with 
mapping data.  The murine chromosome 7 is of intermediate length within the mouse 
genome.  It is 141.7 Mbp in length and codes for roughly 2000 known and novel genes.  
In the context of the congenic mice, the 1.7 cM consensus congenic interval contains 96 
known and novel genes.   This seemingly small number of genes still represents quite a 
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hurdle to attempt a candidate gene search, such that new approaches to established 
technologies were needed. 
Gene microarray technology has been established as the gold standard for transcript 
profiling at the whole genome level.  Recently, its role in complex trait analysis has been 
impressively demonstrated and  ushered in the field of “genetical genomics” (Bystrykh, 
Weersing et al. 2005)  This concept relies on treating gene expression as a complex trait, 
whereby regulators of mRNA levels can be identified.  The approach is similar to a 
traditional mapping experiment, where a specific cell type is transcriptionally profiled 
across a panel of recombinant inbred strains.  These gene expression data can then be 
correlated to not only genomic intervals, but also existing phenotype data.  Thus, this 
approach can advance the search for candidate genes far beyond what is possible with 
traditional approaches.  Furthermore, the use of the congenic strains allows for the 
refinement of the genomic region of interest.  However, the core concept underlying this 
approach is that the complex trait under study is reliant on differential gene expression.  
To understand how other processes may be influencing these traits, a proteomics 
approach should be able to provide insight into post-transcriptional mechanisms. 
 The field of hematology has been slow to embrace the area of proteomics in stem 
cell research.  This is primarily due to the amounts of protein that are needed in the face 
of a vanishingly small population of cells.  In spite of this several studies have recently 
been published that show the utility of analyzing the proteome of various BM populations 
(Evans, Tonge et al. 2004; Unwin, Smith et al. 2006).  Furthermore, proteomics 
experiments relying on 2-D PAGE separation of cellular proteins are not limited by the 
presence of a target sequence on a chip such as a gene microarray.  Thus, current 
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proteomics techniques make it possible to study known as well as unknown  gene 
products present in various cell populations provided they are expressed at a detectable 
level.  Here we have assessed the genomic and proteomic profiles of HPCs from the 
congenic and parental mouse strains in an effort to identify the candidate gene(s) 
underlying the HU-killing QTL.           
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Materials and Methods 
 
Animals 
 Female DBA/2J and C57BL/6J mice, 6-10 weeks of age, were purchased from 
The Jackson Laboratory (Bar Harbor, ME, USA).  Mice were housed under specific 
pathogen free conditions at the University of Kentucky Division of Laboratory Animal 
Resources.  All animal experiments were approved by the Institutional Animal Use and 
Care Committee of the University of Kentucky.  
 
Isolation of RNA  
 Bone marrow was collected as described previously.  BM-MNCs were isolated 
from WBM using a Ficoll density gradient.  Cells were then labeled with LIN, ckit, and 
Sca1 antibodies.  LIN-Sca1-ckit+ progenitor cells were sorted into 1.5 mL centrifuge 
tubes.  Total RNA was isolated from the sorted cells using the Qiagen RNeasy kit 
(QIAGEN, Valencia, CA).  RNA was eluted using sterile, autoclaved water and stored at 
-80oC until analysis by microarray or quantitative real-time PCR.   
 
Microarray Analysis 
 Analysis of total RNA expression was assessed using oligonucleotide gene arrays 
at the University of Kentucky MicroArray Core Facility.  Total RNA was isolated from 
three groups of at least 10 mice for each of the four mouse strains.  At the MicroArray 
Core Facility, RNA was reverse-transcribed and biotin-labeled, followed by 
fragmentation and hybridization of the labeled cRNA to the Mouse Genome MOE430 v.2 
chip (Affymetrix, Santa Clara, CA).  After washing and staining, arrays were scanned to 
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quantify the expression of each probeset.  One-way ANOVA was performed on each 
parental/congenic pair by the University of Kentucky Department of Statistics.  
Significance was established at a p-value of 0.05.   
 
Real-Time PCR 
 Total RNA was isolated from exactly 200,000 progenitor cells from each of the 
four mouse strains.  RNA samples were then reverse-transcribed into cDNA using 
random hexamers for priming in TaqMan® reverse transcription buffer.  Real-time PCR 
reactions were carried out in TaqMan® universal PCR mastermix using primer/probesets 
for the analyzed genes from Applied Biosystems (Foster City, CA).  TaqMan® beta actin 
was used to control for variability in reaction conditions.  Three biological samples from 
each strain were assayed for each candidate gene.     
 
Isolation of Protein 
 Bone marrow aspirates were collected from D2 and D2.B6 mice in HBSS + 2% 
FCS.  Cell suspensions were then layered onto a Ficoll density gradient and centrifuged 
for 30 minutes at room temperature.  The buffy coat containing the mononuclear cells 
was then removed and washed twice with 1X DPBS.  After centrifugation at 1400 rpm 
for five minutes at 40C, cytoplasmic protein was isolated using the ReadyPrep Protein 
Extraction Kit (Cytoplasmic/Nuclear) from Bio-Rad (CA, USA) according to 
manufacturer’s instructions.  The resulting cytoplasmic and nuclear protein samples were 
quantified using a modified Lowry assay (RC DC Protein Assay, Bio-Rad) and  
resuspended to 0.3 and 0.6 mg/ml, respectively, in a 2-D rehydration/sample buffer (7 M 
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urea, 2 M thiourea, 4% CHAPS, 50 mM DTT, 0.2% Bio-Lyte 3/10 ampholyte, and 
0.002% Bromophenol Blue).  Subsequently, equivalency of protein fractionation was 
assayed by western blot to probe nuclear fractions for the presence of thiolase, a 
cytoplasmic-specific protein found in peroxisomes and  mitochondria.  Total cell protein 
from whole bone marrow was used as a positive control.   Blots were stripped and re-
probed for actin to ensure equivalency of protein loading. 
 
2D-PAGE 
A 185 uL aliquot of the normalized protein samples was loaded onto an 11 cm 
immobilized pH gradient (IPG ReadyStrip, pH 3-10, Bio-Rad).  After overnight 
rehydration of the IPG strips, first dimension isoelectric focusing (IEF) was performed at 
room temperature using a PROTEAN IEF Cell (Bio-Rad) for 30,000 V-hr.  After IEF, the 
IPG strips were sequentially equilibrated for 10 minutes each in 4 mL of SDS-PAGE 
Equilibration Buffers I and II, with 2% DTT or 2.5% iodoacetamide, respectively (6M 
urea, 0.375M Tris pH 8.8, 2% SDS, and 20% glycerol).  IPG strips were then loaded onto 
pre-cast Criterion Tris-HCl gels (Bio-Rad) and electrophoresed for one hour.  
Polyacrylamide gels were then fixed in 10% methanol and 7% acetic acid for 1 hour 
followed by overnight staining with Sypro Ruby Red (Invitrogen, Carlsbad, CA).  Gels 
were destained with 10% methanol and 7% acetic acid one hour prior to image 
acqusition. 
 
Image Analysis 
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 The Sypro Ruby Red stained gels were scanned using an Amershan Biosciences 
Typhoon scanner at 200 um/pixel resolution.  Scanned images were analyzed using the 
PDQuest 2D Analysis software (Bio-Rad).  After background fluorescence of each image 
was subtracted, spot density normalization was performed on the basis of the total spot 
density for the same gel.  This allows for the assignment of an arbitrary density value of 
parts-per-million (ppm) while also minimizing gel-to-gel variability arising from 
procedural inaccuracies.  Each scanned gel image from both samples was then assembled 
into a matchset allowing for gel alignment and spot matching.  Gel alignment was 
performed by marking spots present on all gels (landmarks) to compensate for gel 
distortion.  For spot matching, only spots matched in two or more gels of each sample 
were chosen for subsequent analysis.  Every matched spot was then manually reviewed to 
ensure the accuracy of the spot detection.  Analysis of statistically relevant proteins was 
performed using the student’s t-test to compare the normalized spot densities at a p-value 
of 0.05.  Accuracy of protein loading was confirmed by comparing the normalized 
quantity of actin in each gel.    
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Results 
 
Day 7 CAFC killing by HU in sorted LIN-Sca1-ckit+ HPCs 
 The CAFC assay is a retrospective assay, such that the cells that form cobblestone 
areas no longer harbor a progenitor cell phenotype.  Furthermore, total bone marrow is 
comprised of a heterogenous population of cells that could potentially mask HSC/HPC-
specific gene expression profiles.  Thus, we sorted HPCs as defined by their cell surface 
phenotype of LIN-Sca-1ckit+ from HU-treated mice and analyzed the frequency of day 7 
CAFCs killed by HU.  As expected, the fraction of killed progenitor cells from D2 and 
D2.B6 chr.7 mice paralleled that seen in WBM, 37.3±8.1 and 11.2±6.4%, respectively 
(figure 4.1).  Analagously, we observed that sorted progenitor cells from B6.D2 chr.7 
mice exhibited HU-induced killing to a similar degree as WBM (27.2±10.8).  
Surprisingly, we found that the fraction of sorted HPCs from B6 mice was not 
significantly different from that seen in the B6.D2 or D2 HPCs.   
 
Microarray analysis of gene expression in the consensus congenic interval of 
proximal chromosome 7 
 The results given above dictated our approach to analyzing the gene expression 
patterns of the congenic and background HPCs.  First, genes were identified that were 
significantly different between the congenic and parental pair.  Next, the positions of 
these genes were screened to identify those that were in the congenic interval.  Finally, 
the gene expression patterns were analyzed such that a genes showing differential 
expression between the D2 and D2.B6 chr. 7 HPCs were selected for further analysis.  
Theoretically, the genes meeting these criteria should also not show significant 
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differences between HPCs from B6 and B6.D2 chr. 7 mice.  While the Affymetrix arrays 
allow the user to profile the expression of 40,000 transcripts representing 20,000 genes, 
only 90 genes are present in the congenic interval.  In fact, when microarrays were 
performed on the D2 and D2.B6 chr.7 mouse strains, 28,684 transcripts were found to be 
expressed in common between the two strains.  Of these, 1266 were statistically different 
between the two strains at a p value of 0.05.  When we looked only at those genes that are 
located in the congenic interval we found that only the Rps9, Leng9, and Tfpt genes were 
statistically different between the D2 and D2.B6 chr.7 transcriptomes (table 4.1).   
 A second set of microarrays was performed on sorted progenitor cells from the B6 
and B6.D2 mouse strains and compared with the data generated from the D2 vs. D2.B6 
chr.7 microarrays (table 4.2).  Reasoning that only progenitor cells from the D2 and 
D2.B6 exhibited the difference in the HU-killing trait, we looked for genes that were not 
differentially expressed between B6 and B6.D2 chr.7 HSC/HPCs and were differentially 
expressed between D2 and D2.B6 chr. 7 HSC/HPCs.  Again, we found an abundant 
number of transcripts (27073) present in both strains, with only a fraction being 
significantly different between the two strains (1300).  However, of the four differentially 
expressed genes found in the D2.B6 chr. 7 comparison,  all showed significant expression 
differences between the B6 and B6.D2 chr. 7 HSC/HPCs.      
 
Confirmation of the differentially expressed genes in the consensus congenic interval 
of proximal chromosome 7 
 Having found that only four known genes within the consensus congenic interval 
are differentially expressed between D2 and D2.B6 chr. 7 progenitor cells, we determined 
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their gene expression profiles using quantitative real time PCR.  As shown in figure 4.2, a 
candidate gene, Ndufa3, was confirmed to be differentially expressed, with D2 
expression being 40% lower than that of D2.B6 chr.7.  These data are in line with the 
magnitude of gene expression changes found in the microarray experiments.  However, 
when RT PCR was performed on the candidate genes Rps9 and Tfpt, no statistical 
difference was found (data not shown).   
 
2-D PAGE analysis of the mononuclear fraction of BM in D2 and D2.B6 chr. 7 
congenic mice 
 In an attempt to survey other mechanisms underlying the chromosome 7 QTL we 
performed 2-D gel electrophoresis on progenitor-enriched mononuclear cell preparations 
from D2 and D2.B6 chr.7 mice.  Using this approach it is possible to assay for changes in 
protein amounts, peptide length, and posttranslational modifications that are undetectable 
using gene-expression based approaches.  The data presented in figures 4.3 and 4.4 show 
a comparison between 2D PAGE  images of a cytoplasmic protein fraction from D2 and 
D2.B6 chr.7-derived bone marrow mononuclear cells.  A statistical comparison was made 
in which protein levels were compared at each spot between the two samples.  As shown 
in table 4.3, there are more than 200 spots that are significantly different between the two 
BM-MNC populations.  These spots were further analyzed to determine the direction of 
change with respect to the parental D2 strain.  Surprisingly, it was found that only eight 
proteins were overexpressed in D2 BM-MNCs compared to those of D2.B6 chr.7.  
Similarly, when the protein profiles of the nuclear fractions from the same cell 
populations, it was again found that more than 200 spots were statistically different 
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between the two strains (figures 4.5 and 4.6).  However, no proteins in this fraction were 
overexpressed in the D2 sample compared to the D2.B6 chr.7 pool.    
 Further analysis centered on comparison of the expression data generated from 
the microarray experiments and  the 2-D PAGE results.  Molecular weight and pI data 
were determined for each of the candidate genes in the D2.B6 chr.7 congenic interval and 
compared to the corresponding spots on the 2-D gels.  A minimum of 4 proteins in the 
cytoplasmic fraction and 13 in the nuclear fraction (tables 4.3 and 4.4, respectively), are 
potentially located in gel regions containing differentially expressed protein spots.  This 
was based on the criteria that the transcript for the corresponding protein is present in 
HPCs and that the predicted pI was within 1 pH unit of a similarly sized protein spot.   
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Discussion 
 
 The data presented in this chapter provide a comprehensive analysis of the 
genomic and proteomic consequences in HSC/HPCs of moving a genomic interval of 
chromosome 7 between the D2 and B6 mouse strains.  Our findings that a significant 
number of genes are differentially expressed between the parental and congenic  
HSC/HPCs suggest key regulators of transcription are being influenced by the congenic 
interval.  However, using a p-value of 0.05 as the level of significance , it would be 
expected that 1450 transcripts would be falsely identified as significantly different in 
their expression, when in fact they are not.  This is remarkably similar to the number of 
transcripts found in the D2.B6 vs D2 microarrays.  Thus, it is likely that  most of the 
transcripts identified in the microarray analysis are, in fact, not differentially expressed.  
Our findings that the differential expression of 3 of the 4 candidate genes in the congenic 
interval could not be confirmed by real-time PCR seems to support this idea.  
Furthermore, only 71 of the 2565 total transcripts are in common between the two 
datasets.  In spite of this, we were able to confirm differential expression of the candidate 
gene Ndufa3, whose expression is 40% higher in HPCs of D2.B6 congenic mice 
compared to the parental D2 strain.  
 Our unexpected finding that the frequency of sorted HPCs killed by HU was 
higher in B6 compared to WBM and not significantly different from that of B6.D2 chr. 7 
mice supports the data from the competitive repopulation experiments detailed in chapter 
3.  There, it was noted that the chromosome 7 QTL regulates the proliferative response of 
WBM, but not HPCs, at 72 hours post-transplant.  Thus it seems that the cellular 
population that bears the HU-killing trait may differ between the B6 and D2 strains.  One 
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explanation for this observation is the fact that the congenic interval of the B6.D2 chr. 7 
strain is 17Mbp longer than that of the D2.B6 chr. 7 mice.  It is possible that this region 
harbors other genes that affect HU sensitivity of HSC/HPCs that were not detected by the 
initial QTL mapping.  A second possibility is that the time course of cobblestone 
formation is slightly different between LIN-Sca1-ckit+ HPCs of D2 and B6 mice.  This 
idea is similar to the report that the time course of cobblestone forming ability of sorted 
LIN-Sca1+ckit+  differ markedly between the D2 and B6 mouse strains (de Haan, 
Szilvassy et al. 2000).  Thus, if the HU-insensitive fraction of LIN-Sca1-ckit+ HPCs 
form cobblestones at a time other than seven days after culture, the phenotype would be 
missed.  In the future it will be necessary to test for this possibility by assessing the 
CAFC cultures at other time points.    
 The protein encoded by the  Ndufa3 gene is purported to be a subunit of complex 
I of the electron transport chain that acts to transfer H+ ions from NADH to ubiquinone.  
This is a vital step in the process to transport H+ ions from the mitochondrial matrix to 
the intermembrane space.  This is responsible for the maintenance of the mitochondrial 
membrane potential, the disruption of which results in the initiation of apoptosis.  While 
we have not yet been able to confirm that these expression differences are mimicked at 
the protein level,  it is hypothesized that greater expression of the protein in B6 and 
D2.B6 HSC/HPCs acts to promote the maintenance of the mitochondrial membrane 
potential in the face of apoptotic stimuli.  An alternative possibility is that increased 
levels of the Ndufa3 gene product shift the NADH ⇒ ubiquinone equilibrium further to 
the right, resulting in decreased amounts of NADH.  It has been reported that HU 
becomes oxidized in vivo, which generates nitric oxide radicals that are able to quench 
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the tyrosyl radical in the active site of ribonucleotide reductase (Jiang, Jordan et al. 
1997). Furthermore, the ability of HU to induce the formation of oxidized nucleotides 
and DNA strand breaks in the presence of Cu(II) is potentiated by the presence of NADH 
(Sakano, Oikawa et al. 2001).  It is possible that reduced in vivo levels of NADH could 
result in decreased levels of DNA damage and thus increase cell survival.  However, our 
data showing similar levels of the DNA damage marker, gamma H2AX, in D2 and B6 
bone marrow cells would seem to argue against this. 
 One obstacle to this gene expression profiling approach is the fact that not all 
genes present in the congenic interval are interrogated by the microarray.  A recent report 
comparing the transcriptomic coverage of various microarray platforms has determined 
that of the 90 known/novel genes in the congenic interval, only 67 are probed by the 
M430 2.0 array (Verdugo and Medrano 2006).  However, most of these transcripts are 
either novel genes or members of the olfactory/vomeronasal receptor family and thus 
were excluded from our analysis.     
 The results of the microarray experiments speak to the significant role that the 
chromosome 7 QTL plays in  the regulation of gene expression.  However, the 
relationship between mRNA levels and protein abundance in a cell shows surprisingly 
variable correlation (Gygi, Rochon et al. 1999).  In an attempt to understand the 
proteomic changes that occur upon introgressing the chromosome 7 QTL from B6 to D2 
mice, we performed 2-D PAGE analysis of BM-MNCs.  While BM-MNCs are not 
considered to be a purified stem or progenitor cell population, we have shown that the 
frequency of HSC/HPCs is similar between the two mouse strain.  Thus, any skewing of 
the protein abundance is not due to a difference in the representation of different cell 
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types in the BM-MNC population.  More importantly, the scarcity of the progenitors 
(~0.1%) in bone marrow precludes their study at the proteomic level.  Recent studies 
have attempted to circumvent this problem by using a novel technique of labeling protein 
populations from two samples  with different fluorphores and admixing them prior to 2-D 
PAGE ((Evans, Tonge et al. 2004).  However, this technique is still in its infancy and the 
reproducibility of the dye-labeling remains a significant hurdle for accurate analysis.  
Other studies have relied on the use of hematopoietic cell lines or minimally enriched cell 
fractions such as CD34+ umbilical cord blood cells (Tao, Wang et al. 2004)  While these 
studies all used unfractionated cell lysates for their analysis, the high abundance proteins 
such as albumin and actin can often mask the expression of less abundant proteins.  Thus, 
these studies are drastically skewed toward only the most abundant proteins.  To address 
this issue, we isolated the nuclear and cytoplasmic protein fractions of BM-MNCs and 
analyzed them using a traditional 2-D PAGE approach.   
 The ultimate goal of these studies was to identify a manageable number of 
candidate proteins that could be involved in the HU-killing phenotype.  It was hoped that 
the use of congenic strains would assist in minimizing the number of differentially 
expressed proteins that would be detected in a 2-D gel.  Surprisingly, we found a large 
number of proteins were overexpressed in the nuclear and cytoplasmic D2.B6 samples 
compared  to that of D2 samples.  However, only a very few proteins were overexpressed 
in the cytoplasmic fraction of D2 and none in the nuclear fraction compared to D2.B6.  
This finding would seem to suggest that the B6 congenic interval imparts at least a 
significant protein translation, if not gene activation, effect upon the D2 genome.  These 
data also seem to contrast with what was seen in the gene microarray experiments.  There 
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we found that 1266 transcripts were significantly different between the D2 and D2.B6 
chr.7 HSC/HPCs.  However, the direction of expression changes of these transcripts was 
not biased in either direction.  While noting that the proteomic and genomic data were not 
derived from the exact same cell populations, these data support the supposition that a 
poor correlation exists between mRNA levels and protein abundance.     
 To our knowledge, this is the first time that proteomic profiles of congenic mouse 
strains have been compared, and represents a novel approach to identify potential 
candidates.  With a defined congenic interval that regulates HU-killing of HSC/HPCs, it 
is possible to align the individual genes with their expected migratory patterns in a 2-D 
gel.  Using the Swiss-prot online 2-D PAGE database, we computed theoretical 
molecular weights and isoelectric points for each of the genes in the congenic interval.  
These data were then compared to the Mr and pI dimensions of the spotted proteins to 
identify potential candidates.  While the discussion of specific candidate genes using this 
approach is a bit premature, it is exciting to note that a spot aligning with the Tfpt gene 
product is differentially present between the two strains.  This gene has been reported to 
be involved in cell cycle control and apoptosis induction when overexpressed in a human 
cell line (Irie, Yamagata et al. 2000; Gan, Taira et al. 2003)   Furthermore, the amount of 
protein in the aligned spot is significantly higher in D2 than in D2.B6 chr.7, as might be 
expected.  
 The studies undertaken in this chapter are based on the supposition that the 
response of HSC/HPCs to HU is due to a factor(s) that is present during steady-state 
hematopoiesis.  This hypothesis is supported by data given in chapter 3, where it was 
shown that surviving bone marrow cells have recovered from the HU insult by 3 hours to 
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re-enter the cell cycle.  While studies have shown that the administration of HU causes a 
significant transcriptional response in the cell within four hours (Muller, Boitier et al. 
2005), our data suggest that the cytotoxic effects of HU occur over a much shorter time 
course that could not allow for such a response to improve survival.  It is also possible 
that HU administration initiates a significant translational response from an existing 
mRNA pool.   If this were the case, then a microarray approach should still lead to the 
identification of the candidate gene(s).  Finally, it is possible that the response is affected 
by sequence differences at the protein level that could only be observed after HU 
treatment, given the vast number of post-translational modifications that occur in 
response to HU.  Thus, it maybe of benefit to perform 2-D PAGE analysis of BM-MNCs 
after HU treatment.           
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Figure 4.1  Day 7 CAFC killing by HU of sorted LIN-Sca1-ckit+ HPCs.   
For each mouse strain, a minimum of three independent pools of bone marrow from 3 
mice each were analyzed for the fraction of day 7 CAFCs killed by HU.  * p < 0.05 D2 vs 
D2.B6 chr. 7.       
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Table 4.1  Transcripts expressed differentially between D2 and D2.B6 chr.7 HPCs 
Gene Symbol Gene Title Function Basepair (Mbp) 
Fold 
change 
(relative to 
D2) 
Ndufa3 NADH 
dehydrogenase 
(ubiquinone) 1 
alpha 
subcomplex, 3 
NADH 
dehydrogenase 
activity 
3240332 1.3 
Tfpt TCF3 (E2A) 
fusion partner  
--- 3243284 1.7 
Rps9 ribosomal 
protein S9 
protein 
biosynthesis 
3326997 18.6 
Leng9 leukocyte 
receptor cluster 
(LRC) member 
9 
nucleic acid 
binding 
3706244 1.9 
0610042E07Rik RIKEN cDNA 
0610042E07  
--- 4418944 1.7 
 
Genes are listed in order along the chromosome starting at the centromere.  The congenic 
interval is bounded proximally by the centromere (0-3 Mbp) and distally by D7Mit75 
(6.3 Mbp).  
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Table 4.2  Transcripts differentially expressed between B6 and B6.D2 chr.7 HPCs 
Gene symbol Gene title Function 
Basepair 
(Mbp) 
Fold 
change 
(relative 
to 
D2.B6 
chr. 7) 
Ndufa3 NADH 
dehydrogenase 
(ubiquinone) 1 
alpha 
subcomplex, 3 
NADH 
dehydrogenase 
activity 
3.2 1.2 
Tfpt TCF3 (E2A) 
fusion partner 
--- 3.2 1.6 
Prpf31 Pre-mRNA 
processing 
factor 31 
assembly of 
spliceosome 
3.2 0.7 
Rps9 ribosomal 
protein S9 
protein 
biosynthesis 
3.3 14.8 
Pirb  Paired 
immunoglobulin-
like receptor b 
B-cell 
homeostasis 
3.3 0.6 
Cox6b1 cytochrome c 
oxidase, subunit 
VIb polypeptide 
2 
electron transport 4.3 0.9 
2210411K11Rik RIKEN cDNA 
2210411K11 
--- 4.3 0.8 
0610042E07Rik RIKEN cDNA 
0610042E07 
--- 4.4 3.7 
 
Genes are listed in order along the chromosome starting at the centromere.  The congenic 
interval is bounded proximally by the centromere (0-3 Mbp) and distally by D7Mit57 (23 
Mbp).  Only genes within the consensus congenic interval of 0-6.3Mbp are shown.
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Figure 4.2  Quantitative RT-PCR analysis of the candidate gene Ndufa3 between the 
D2 and D2.B6 chr. 7 strains.    
Total RNA was isolated from 4 independent samples of 200,000 HPCs.  Four replicates 
of each sample were analyzed with the Ndufa3 primer/probe.  Data were normalized to 
the expression of the housekeeping gene beta-actin.  Values are mean ± SEM.  P < 0.05.
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Figure 4.3  2-D PAGE of the cytoplasmic protein fraction from D2 BM-MNCs.    
A representative 2-D PAGE gel detailing the migratory profile of D2 cytoplasmic 
proteins in a bone marrow cell fraction that is enriched for HSC/HPCs. 
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Figure 4.4  2-D PAGE of the cytoplasmic protein fraction from D2.B6 chr. 7 BM-
MNCs 
A representative 2-D PAGE gel detailing the migratory profile of D2.B6 chr. 7 
cytoplasmic proteins in a bone marrow cell fraction that is enriched for HSC/HPCs. 
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Table 4.3  Alignment of differentially expressed cytoplasmic protein spots and known 
genes in the congenic interval.
Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
10.2 6.8 1544.7
Cox6b2 10.5 9.8 ND
10.7 5.5 24201.9 6383
10.9 5.3 1759.6
Ndufa3 11.2 9.9 B6>D2
11.5 6.6 360
11.7 5.3 1901.8
12.5 4.8 1134.9
12.5 7.4 718.8
12.9 5.2 622.3
13.2 6.4 1108.1
13.2 7.3 492.3
13.3 - 612.7
13.4 - 27630.7
13.4 7.6 31313 2961.5
13.5 6.7 34272.2
13.7 - 4240.8
13.7 7.3 1198.4
13.9 6.4 5534.3
13.9 8.2 10241.2
14.5 6.3 546.2
14.7 4.7 919.2
14.7 - 1292.4
14.7 - 3658.6 2267.3
14.7 - 1344.8
14.7 5.2 1494.3 944.4
Cdc42ep5 15.5 6.1 ND
16.3 5.2 1653.1 1060.2
16.4 7.6 332.7
16.6 - 269.7
16.8 5.9 433.1
16.9 5.7 898.7
17 8.0 1631.4
17.2 5.2 560.2
17.2 6.6 615.9
17.2 - 405.4
17.2 - 1342.9
17.5 6.0 680.9
17.8 7.9 4058.2 2153.6
17.8 7.5 4535.6 2171.9
17.9 6.7 906.1
17.9 7.2 1011.7
18 7.1 794.3 313.4
18.2 6.5 463.4
18.3 6.9 877.3
18.3 5.6 950.6 232.3
18.4 7.2 580.2
18.4 8.3 3063.2 1798.2
18.5 - 810.8
18.5 - 623
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
18.7 5.3 3060.4 1500.5
18.7 - 2714.8
Zfp580 18.8 10.1 Not expressed
19 - 586.1
19.6 4.9 423
Zfp371 20.3 9.6 Not expressed
20.7 5.6 817.5
20.7 6.9 476.9
21.2 - 412.3
21.5 6.6 533.6
21.5 5.0 1489.1
Galp 21.5 7.8 Not on chip
21.6 7.4 243.4
21.7 - 846.5
22 - 313.1
22 7.3 308.9
22.3 6.7 1047.8 587.8
22.4 5.4 737.1
22.4 - 749.4
22.5 6.4 457.2
Rps9 22.5 10.7 B6>D2
22.7 6.1 341
22.8 6.8 849.8
23 4.8 472.6
23.7 7.3 723.6 361.9
23.7 7.6 275.7
23.7 6.8 594.6
23.8 6.5 1224.5
23.8 - 1111
23.8 7.3 867
23.9 5.4 642.5
24.2 6.3 519.3
Ube2s 24.2 7.7 ND
24.6 5.5 555.7
24.6 6.6 961.2
24.8 8.1 504.7 253.9
24.8 7.5 755.3
25 7.7 547.7
25 7.2 214.4
Tmem86b 25 6.2 Not expressed
25.1 - 286.4
25.2 5.8 217.7
25.4 7.4 157.7
26.1 5.3 517.8
26.2 5.1 394.3
26.2 6.8 206.8
27.2 - 317
27.2 - 439.9
27.3 - 220.1
27.3 6.3 230.1
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
27.3 6.5 389.5
27.3 5.3 260.9
27.4 7.4 395.8
27.5 6.2 281.8
27.6 6.9 389.6
27.7 6.8 451.4
27.8 7.1 1756.6 1180.5
27.8 - 1743.2 1001.5
27.9 6.4 203.2
28 8.0 356.3
28.4 6.8 346.5
28.7 6.1 317.7
Oscar 28.7 6.9 Not expressed
Tfpt 28.9 4.9 ND
29.1 7.8 189.4
29.5 6.8 158.4
Lair1 29.8 5.6 ND
30.7 7.0 435.3
31 5.2 377.2 1392.1
31.4 6.0 1061
31.7 5.1 304.2
32.1 6.4 494
Rfpl4 32.3 7.5 Not expressed
32.5 6.5 308.9
32.7 7.2 331.5
33.3 6.9 383.4
34.1 5.8 452.7
Tsen34 34.2 6.6 Not expressed
34.3 6.8 555.5
34.7 5.9 395.9
Zfp524 34.8 8.9 Not expressed
35.4 5.2 176.9
Zfp444 35.8 8.9 ND
35.9 6.1 1513.8 555.2
36.2 6.7 579.6 276.7
36.4 7.3 153.3
36.5 7.2 304.1
Rdh13 36.5 9 ND
36.9 7.7 165.9
Ncr1 37.3 7.6 ND
39.8 8.2 273.6
40.1 - 518.5
40.4 6.6 361.8
40.6 - 425.6
40.9 6.9 348
41.7 - 1244.2
41.7 - 1447.4
41.7 8.2 194.8
41.7 8.2 1052
41.8 - 149.9
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
41.8 7.2 339.7
41.8 7.9 450.8
41.8 6.8 221.1
42 6.3 1209.4
42 7.7 279.1
42.3 5.9 402.1
42.4 - 371.8
42.4 6.1 363.6
42.6 7.1 293.2
42.7 8.2 332.1
42.8 6.0 427
42.8 4.9 109.4
43.1 7.2 264.6
Syt5 43.1 9.6 Not expressed
43.5 5.2 389.8
43.5 6.7 458.4
43.6 7.6 233.9
43.6 7.7 166.4
43.8 7.4 186.2
44 5.7 216.6
44.1 7.5 490.7 251.6
44.2 - 290.7
44.7 6.9 224.2
44.8 6.6 960.3 279.2
44.9 5.2 192.1
45.1 7.1 212
45.2 5.9 318.4
45.5 5.5 235.2
46 7.8 133.4
46 7.6 118.9
Leng9 46.1 5.3 B6>D2
46.3 6.7 594.4
46.5 - 203.8
46.6 - 118.1
Il11 46.7 6.1 Not expressed
47.1 5.3 158.9
47.3 5.3 307.7
47.6 5.9 695.8
48.1 6.2 509.1
48.8 - 333.4
49.2 - 483.4
Ttyh1 49.4 5.8 Not expressed
49.7 8.1 274
49.8 6.1 849
50.1 5.1 369.5
50.4 5.5 381.9
51.1 6.8 368.6
51.1 7.1 189.7
51.2 8.1 523.5
51.5 8.2 469.9
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
51.6 7.7 184.4
51.6 6.7 355.2
52 5.9 244.6 598
Fiz1 52.7 8.3 ND
52.8 6.1 357.6
52.8 4.7 620.3
52.9 7.2 1455.9
53 5.5 1202.8
Suv420h2 53.1 9.27 ND
Leng4 53.4 8.9 ND
54.3 7.8 1521.8 660.2
54.4 7.5 400.8
Prpf31 55.4 5.6 Not expressed
55.6 4.9 3742.7
56 - 620.8
56.4 5.1 473.9
56.6 7.9 658.1
56.8 7.0 189.8
57 5.6 812.2
57.1 - 800.7
57.6 - 301.5
58.4 6.6 236.4
Zfp78 58.9 9.4 ND
59.7 5.5 260.4
59.9 5.4 212.6
Zfp579 60.8 9.1 Not expressed
61 6.5 421.5
61.5 5.2 701.2
61.8 5.7 397.5 585.3
62.4 7.2 128.6
62.7 6.9 426.1
63 6.8 351.7 937
63.2 6.3 1057.2 430.5
63.2 6.7 239
63.3 6.9 494.7 1233.4
63.4 5.3 1308.4
63.5 7.8 289.2
63.6 7.3 256.3
Zfp583 65.7 9.1 Not expressed
66.8 7.3 908.4
67 7.0 960.6
Zfp667 70.3 9.8 Not expressed
Pira11 70.6 8.4 ND
71.1 5.4 1304.9
73.5 5.8 1161.6
74.5 7.0 150.2
74.8 5.9 187
75 6.6 523.1
76.6 5.6 748.2
Tmc4 77.3 9.1 Not expressed
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Gray rows indicate known genes in the congenic interval of D2.B6  chr. 7 mice.  
Theoretical molecular weights and pIs were calculated using SwissProt’s prediction 
program (http://www.expasy.org/sprot).  ND:  Not significantly different between D2 and 
B6 alleles of congenic and background mice.   
Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
81.9 5.5 259.8 546.3
Cnot3 81.9 5.8 Not expressed
83.8 7.4 295.2
Ppp1r12c 84.7 5.7 ND
Brsk1 85.1 9.4 Not expressed
Leng8 86.8 9.4 ND
88.3 6.3 350.5
93.3 5.3 284.3 804.4
Zfp28 93.3 9.4 ND
Saps1 94.5 4.5 ND
96.9 7.0 362.4
97.3 6.2 458.9
98.3 6.9 317.2 593.2
98.7 5.1 450.3
98.8 6.0 308.8
99.1 5.5 285.1
Zc3h3 103 10.6
106.3 5.6 230.4
106.4 5.9 171.9
107.6 5.7 260.9
Zfp628 109 8.5 ND
Nalp4c 112.7 6.5
113.7 5.9 1016.4 430.5
Nalp2 118.6 6.3 Not on chip
Ptprh 163 6.4 Not on chip
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Figure 4.5  2-D PAGE of the nuclear protein fraction of D2 BM-MNCs 
A representative 2-D PAGE gel detailing the migratory profile of D2 nuclear proteins in  
a bone marrow cell fraction that is enriched for HSC/HPCs. 
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Figure 4.6  2-D PAGE of the nuclear protein fraction of D2.B6 chr.7 BM-MNCs.   
 
A representative 2-D PAGE gel detailing the migratory profile of D2 cytoplasmic 
proteins in a bone marrow cell fraction that is enriched for HSC/HPCs. 
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Table 4.4  Alignment of differentially expressed nuclear protein spots and known genes 
in the congenic interval.
Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
Cox6b2 10.5 9.8 ND
Ndufa3 11.2 9.9 B6>D2
14.1 6.1 343.2
15.0 5.0 4000.8
15.0 5.2 4944.1
15.2 6.2 1052.5
15.2 - 1131.6
15.4 6.7 1294.0
15.4 5.3 7219.6
15.5 4.6 1387.2
Cdc42ep5 15.5 6.1 ND
15.9 5.4 1424.4
15.9 6.8 14037.6 3429.2
15.9 5.0 1607.6
15.9 8.5 17803.5 3867.5
16.0 6.5 1856.5
16.1 8.2 4385.1
16.3 6.1 10797.4 1141.4
16.4 5.9 2642.9
16.4 5.8 1516.2
16.7 4.7 1571.0
16.9 5.0 3110.6
16.9 4.2 1997.5
17.1 6.5 620.0
17.2 6.9 518.4
17.3 8.6 729.8
17.4 - 689.4
17.4 - 478.1
17.5 - 598.8
17.5 8.0 3623.9 2070.8
17.5 4.6 875.1
17.5 5.2 744.8
17.6 5.8 971.1
17.7 5.6 646.1
17.7 4.5 910.2
17.7 4.2 5767.9 1002.6
17.8 6.2 1241.6 751.6
17.9 - 948.0
17.9 5.9 1198.0
17.9 6.3 2554.4 1226.5
18.0 4.5 453.9
18.2 4.3 207.7
18.2 5.1 4387.7 2477.1
18.2 8.1 1592.4
18.2 7.5 787.3
18.2 6.4 3029.7
18.3 6.1 778.6
18.5 8.6 2383.3
18.5 5.8 576.6
18.7 6.0 1292.8
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
18.7 - 7060.9 3285.8
18.7 - 1631.8
Zfp580 18.8 10.1 Not expressed
18.8 5.0 258.6
19.0 4.7 1704.5
19.3 5.1 1613.4
19.6 4.6 1436.5
19.7 6.1 415.6
19.8 4.5 642.4
20.0 4.9 936.2
20.1 5.3 328.1
20.2 4.2 928.4
20.3 5.1 1792.8
Zfp371 20.3 9.6 Not expressed
20.5 6.3 899.6
20.6 6.0 475.9
20.9 6.7 399.7
21.1 6.2 1485.2
21.3 7.5 377.9
Galp 21.5 7.8 Not on chip
21.6 - 2564.6 919.1
21.6 5.5 867.5
21.7 6.5 1397.1
21.8 5.9 586.9
22.0 5.8 1508.6
22.0 6.3 1461.7 889.3
22.1 6.3 776.7
22.3 5.1 2950.3
Rps9 22.5 10.7 B6>D2
22.6 6.4 1879.8
22.8 6.6 1212.6
23.0 5.8 1873.0
23.1 6.3 2032.8
23.3 - 363.2
23.8 6.1 1714.4
24.0 5.4 855.5
24.0 6.0 410.0
Ube2s 24.2 7.7 ND
24.3 5.1 3033.8
24.6 7.9 370.8
24.9 6.2 666.4
Tmem86b 25 6.2 Not expressed
25.0 5.4 584.0
25.4 - 460.4
25.4 5.8 424.9
25.4 6.7 377.8
25.5 6.1 206.9
25.7 6.8 1197.3
25.8 8.1 227.9
26.5 5.3 1396.3
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
26.6 6.0 266.6
26.7 5.1 399.4
26.8 - 492.2
26.9 6.3 288.9
27.3 6.0 116.0
27.6 5.2 1528.6
27.6 5.8 659.7
28.4 6.4 250.5
28.6 - 486.3
28.7 4.3 892.2 1499.4
28.7 6.3 509.1
28.7 6.4 387.2
28.7 5.2 496.4
28.7 6.0 455.8
28.7 6.0 353.7
28.7 4.8 792.8
28.7 5.3 789.9 1881.3
Oscar 28.7 6.9 Not expressed
28.7 5.1 710.0
28.7 6.2 994.4
28.7 5.5 735.4
28.8 5.4 445.7
28.8 4.3 511.5
28.8 6.8 169.2
28.8 5.8 260.9
28.8 4.7 2262.1 3329.7
Tfpt 28.9 4.9 ND
29.0 5.9 914.0
Lair1 29.8 5.6 ND
30.6 5.3 1036.2
31.0 5.0 495.1
31.4 6.0 308.9
31.5 6.4 448.8
Rfpl4 32.3 7.5 Not expressed
32.7 6.1 377.6
33.0 6.3 421.3
33.0 5.6 571.9
34.0 5.2 406.3
Tsen34 34.2 6.6 Not expressed
Zfp524 34.8 8.9 Not expressed
Zfp444 35.8 8.9 ND
Rdh13 36.5 9 ND
36.6 4.5 428.4 879.7
Ncr1 37.3 7.6 ND
37.4 4.8 321.7
37.5 7.4 1005.0
37.6 6.0 428.1
37.7 6.4 589.5
38.2 5.8 1267.5
38.2 5.5 648.2
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
38.3 6.5 308.2
38.4 5.6 352.9
38.5 4.7 904.7
38.8 5.9 2143.6 1040.0
39.1 6.6 136.9
39.5 7.1 305.1
39.6 5.6 421.9
40.2 6.6 234.6
40.5 5.8 743.5
40.8 8.2 461.6
40.9 8.8 1514.5
41.0 6.4 514.3
41.7 - 615.4
41.8 5.9 306.9
41.8 5.0 632.3
41.8 6.1 532.5
41.9 5.6 359.6
42.2 7.2 426.0
42.4 8.7 3662.8
42.6 6.6 533.4
43.0 6.4 305.2
Syt5 43.1 9.6 Not expressed
43.1 5.9 573.3 1970.7
43.2 6.1 580.5
43.3 4.9 272.5
43.3 5.8 272.1
43.4 6.0 335.5
44.2 6.1 242.3
44.2 6.7 226.6
44.3 8.0 2212.5 2885.7
44.4 5.0 710.6
44.6 7.6 175.3
44.9 - 342.6
45.0 6.5 391.7
45.0 5.8 366.7
45.0 5.5 4377.1 8178.2
45.1 6.4 387.6
45.2 6.1 200.7
45.4 4.8 120.6
Leng9 46.1 5.3 B6>D2
46.2 5.5 1322.0
46.2 5.2 678.1
46.4 6.1 396.4
46.5 6.8 191.5
Il11 46.7 6.1 Not expressed
46.7 7.5 193.1
46.7 8.0 337.1
46.9 6.6 697.7
47.1 6.2 295.9
47.7 6.9 297.7
 102 
 
Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
47.9 5.2 883.7 2636.7
48.5 8.8 179.3
48.6 - 164.3
48.6 6.3 340.0
Ttyh1 49.4 5.8 Not expressed 
49.5 5.2 541.0
50.0 4.6 616.4
50.0 4.2 99.5
50.3 6.0 2859.4
51.5 5.7 461.7 993.6
51.6 6.2 576.8
52.2 6.5 287.2
52.2 4.8 620.7
52.3 6.3 324.0
52.5 4.4 754.5
52.6 6.2 353.0
Fiz1 52.7 8.3 ND
52.7 6.4 413.6
Suv420h2 53.1 9.27 ND
53.2 5.6 689.6
Leng4 53.4 8.9 ND
53.5 6.6 1828.0 632.8
54.0 5.1 11079.2 22284.1
54.3 6.3 496.2
54.3 4.7 1464.7 3615.1
55.0 6.2 627.3
55.2 7.7 1462.8 697.1
Prpf31 55.4 5.6 ND
56.1 6.1 246.8
56.2 6.3 351.9
56.3 8.2 506.5
57.5 6.5 145.2
58.0 6.2 98.3
58.1 4.9 1929.6
58.8 6.6 1784.1
Zfp78 58.9 9.4 ND
59.4 6.5 184.1
59.7 5.9 551.8
60.2 5.8 553.6
60.4 5.6 545.3
60.7 6.0 152.0
Zfp579 60.8 9.1 Not expressed
61.3 8.5 148.6
62.0 4.8 657.0
63.3 5.5 1013.7 1993.4
63.5 5.8 1556.3 5090.1
64.4 6.0 733.5
64.9 6.3 650.1 1304.5
65.0 6.2 190.4
65.5 5.6 468.6
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
Zfp583 65.7 9.1 Not expressed
65.9 5.9 1245.5
66.2 4.4 1270.5
66.8 8.4 151.0
67.2 6.5 1821.2
68.5 6.1 274.7
69.1 5.0 175.8
69.6 8.0 173.4
69.7 4.8 194.8
69.8 8.2 248.0
70.0 5.5 5902.9 16261.0
70.2 4.9 161.6
Zfp667 70.3 9.8 Not expressed
Pira11 70.6 8.4 ND
71.2 5.3 2831.8 6023.9
72.3 5.8 229.7
74.3 5.9 562.0
74.6 6.2 980.0 596.4
75.2 6.0 505.2
75.2 5.1 4175.1 6426.1
77.3 5.7 228.7
Tmc4 77.3 9.1 Not expressed
78.7 5.6 317.5
79.0 4.9 263.1 600.2
80.2 5.9 445.9
Cnot3 81.9 5.8 Not expressed
83.3 5.7 476.3
84.2 - 573.6 1557.5
84.2 6.4 389.6
Ppp1r12c 84.7 5.7 ND
Brsk1 85.1 9.4 Not expressed
85.37 6.23 778.8
Leng8 86.8 9.4 ND
87.22 5.13 3294.4
88.14 5.59 700.3 2307.8
88.15 6.03 335.6
90.15 4.49 995.5 3247.3
90.59 5.54 258.2
91.04 5.87 157.9
91.73 4.92 500.5
91.78 5.52 159.6
92.28 5.29 1852.7 4535.1
92.9 5.19 748.1
Zfp28 93.3 9.4 ND
94.15 6.01 233.3
Saps1 94.5 4.5 ND
94.63 6.09 488.4
95.48 5.59 814.1
98.41 5.35 2477.8
101.52 5.09 301
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Grey rows indicate known genes in the congenic interval of D2.B6  chr. 7 mice.  
Theoretical molecular weights and pIs were calculated using SwissProt’s prediction 
program (http://www.expasy.org/sprot).  ND:  Not significantly different between B6 and 
D2 alleles of congenic and background mice, respectively.  
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Gene ID MW (kD) pI
D2.B6 chr. 7 
(ppm)
D2      
(ppm)
Microarray 
Expression
102.1 5.8 347.7
102.3 6.0 310.3
Zc3h3 103 10.6 Not on chip
103.9 5.3 1201.3 4441.2
Zfp628 109 8.5 ND
110.8 5.8 726.2
112.5 5.9 262.0
Nalp4c 112.7 6.5 Not expressed
113.0 5.1 407.0
117.7 5.7 191.1
Nalp2 118.6 6.3 Not on chip
122.6 5.9 427.1
130.9 4.7 508.6
Ptprh 163 6.4 Not on chip
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CHAPTER FIVE 
GENERAL DISCUSSION 
 The overall hypothesis of this proposal is that the response of hematopoietic stem 
and progenitor cells to the chemotherapeutic agent hydroxyurea is regulated by a gene(s) 
on proximal chromosome 7.  While hydroxyurea has been in existence for more than a 
century, it is still a relevant drug in the clinic.  It is currently advised for the treatment of 
chronic myelogenous leukemia, polycythema vera, and sickle cell anemia.  Furthermore, 
its safety profile and relatively mild  side effects, make it a rather innocuous choice for 
patients needing immediate lowering of their blood cell counts.  Past uses of HU were 
indicated in acute myelogenous leukemia and various solid tumors.  However, the 
efficacy of hydroxyurea in these cases was severely limited and its use discontinued in 
the 1970’s.  The mechanisms that govern the susceptibility of tumor cells to HU are 
poorly understood, mostly due to the limited knowledge of how HU interacts with the 
replicative machinery and its metabolism.  It is known that not all tissues are susceptible 
to the actions of HU, specifically adipose and bone.  However, lymphocytes are 
particularly adept at concentrating HU with significant variability between individuals.   
In chapter two, we found that the HSC/HPCs of D2 mice are selectively killed compared 
to those of B6 and that this is regulated by a locus on proximal chromosome 7.   
 Our data showing that a gene(s) is present in the B6.D2 chr. 7 mouse strain that 
regulates HPC frequency is an exciting finding.  The mechanisms that regulate the size of 
the stem and progenitor cell pools in the bone marrow is an area of intense investigation.  
In the clinic, HSC/HPCs are harvested from three main sources:  bone marrow, mobilized 
peripheral blood, and umbilical cord blood.  However, in the case of the latter two, it is 
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almost impossible to retrieve enough progenitor cells from a single donor to engraft an 
adult.  Thus, the discovery of molecules that regulate this trait could potentially be 
exploited to amplify the number of HSC/HPCs recovered from these sources.  In the 
future, it will be necessary to confirm these results using cell culture and in vivo bone 
marrow reconstitution assays. 
 Our findings in chapter three largely confirm results established by other labs.  In 
particular, the findings that cells recover from cell cycle arrest and de-phosphorylate 
gamma-H2AX 3 hours after HU speaks to the rapidity with which HU acts in the cell.  
While the congenic locus on chromosome 7 does not regulate the survival of S-phase 
cells after HU in the D2 mouse strain, the fact that the D2 allele imparts a significant 
proliferative advantage after bone marrow transplant suggests that the regulation of cell 
cycle control underlies the HU-killing trait.   These data further pose an interesting 
question of what cell type is responsible for this proliferative advantage, since LIN-Sca1-
ckit+ HPCs did not possess this trait.  Our findings that this same population is as 
sensitive to HU killing in B6 as in B6.D2 chr. 7 mice suggest that the identification of 
HPCs may not be as stringent as it is in the D2 mouse strain.  Thus a more accurate 
profiling of CAFC frequencies at time points other than those traditionally used is likely 
to shed light on how HPCs from D2 and B6 mice behave in vitro.  It will also be 
interesting to determine whether this phenomenon has an in vivo correlate. 
 Congenic mice allow us to study QTL in isolation of the parental genetic 
background, and thus serve as a springboard for defining specific genes that regulate the 
trait.  Using a combination of gene expression and proteomic profiling, the specific 
mRNA and protein expression effects of the QTL can be defined and teased apart.  
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Indeed our microarray data underscore just how genetically similar the parental and 
congenic strains are.  At most we found that roughly four percent of the expressed 
transcripts in HSC/HPCs are regulated by the chromosome 7 congenic interval.  
Furthermore, only four known genes in the congenic interval were differentially 
expressed between the D2 and D2.B6 chr.7 HSC/HPCs.  One of these, Ndufa3, was 
confirmed using quantitative RT-PCR, and thus is a primary candidate for further study.   
 Not much is known about this particular nuclear-encoded subunit of the electron 
transport chain’s complex I.  However, other subunits of this protein complex have been 
shown to play a role in various mitochondriocytopathies.  For instance, the NDUFS4, 
NDUFS7, NUDFS8, and NDUFV1 subunits of complex I have all been found to harbor 
mutations underlying complex I deficiency (van den Heuvel and Smeitink 2001).  The 
incidence of these deficiencies of complex I has been estimated to occur in 1 out of every 
10,000 live births, and is often fatal during childhood (Triepels, van den Heuvel et al. 
2001).  Given the pathways affected, it is understandable that tissues that have high 
metabolic activity would be most susceptible to complex I deficiency.  However, the 
metabolic demands of HSC/HPCs have not been well characterized.  Moreover, the 
traditional approach of isolating HSCs based upon their low uptake of rhodamine 123 (a 
mitochondrial-specific dye) has been interpreted to mean that HSC have few active 
mitochondria.(Bertoncello, Hodgson et al. 1985)  If these cell types are assumed to have 
a relatively low metabolic demand then it is understandable that they could well tolerate 
variation in the stoichiometry of protein subunits in complex I with little or no effect on 
cell viability.  Thus, it is not surprising that variation in the Ndufa3 gene occurs at the 
transcript level between D2 and D2.B6 HSC/HPCs.   
 108 
 In order to validate Ndufa3 as the gene underlying the chromosome 7 QTL it will 
be necessary to 1) confirm its expression at the protein level and 2) to show that HU 
sensitivity of HSC/HPCs is affected by perturbing Ndufa3 expression.  The former step 
is, as of now, hindered by the lack of a commercially or privately available antibody.  
However, the latter step could be accomplished through either small interfering RNA-
mediated  (siRNA) knockdown or retrovirally-mediated overexpression  of Ndufa3.  
RNA interference (RNAi) is a novel technology that relies on the intracellular injection 
of short sequences of RNA that are complementary to the target gene mRNA sequence.  
Upon binding of the siRNA to its  target mRNA, the resulting duplex is targeted for 
degradation by RNA-induced silencing complexes (RISCs) (Uprichard 2005).  With 
steady-state protein degradation no longer balanced by protein synthesis, the levels of the 
mRNA-encoded protein are decreased.  In accordance with the working hypothesis, this 
RNAi-mediated knockdown of Ndufa3 should result in increased killing of HSC/HPCs 
treated with HU.  In contrast, overexpression of Ndufa3 by a retroviral construct should 
decrease killing of HSC/HPCs in response to HU.      
 It is possible, however, that the Ndufa3 gene product is not responsible for the 
variability in the sensitivity of HSC/HPCs to HU.  Thus, we have undertaken a 
proteomics approach to identify proteins that are regulated by the congenic interval.  The 
area of proteomics is currently undergoing a revolution of sorts, the goal of which is to 
define the entire repertoire of proteins in a given cell type.  Gene microarray technology 
has been exhaustively exploited to try to identify the transcriptomic profile of HSCs 
(Ivanova, Dimos et al. 2002; Ramalho-Santos, Yoon et al. 2002; Fortunel, Otu et al. 
2003).  However, the relationship between mRNA levels and protein abundance is 
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tenuous at best.  Our attempt to compare the proteomic and genomic profiles of bone 
marrow cells is hardly a novel idea.  What is novel is the use of congenic strains that now 
allow us to assess the proteomic changes that occur by introgressing a genomic region 
from one mouse strain to another.  Furthermore, with the considerable gene annotation of 
proximal chromosome 7 we can now correlate the proteomic profiles with the predicted 
molecular weights and isoelectric points of the congenic genes.  The next step will be to 
isolate spots that potentially correlate to the known genes and use mass spectrometry to 
learn the identity of the protein.  If successful, this approach could be applied to other 
congenic and consomic strains that possess physiologically relevant traits. 
 Understanding the modifiers of HU-susceptibility in HSC/HPCs would help to 
more effectively target specific tumor types, through screening for the presence of these 
modifiers.  Furthermore,  in the realm of cancers of the bone marrow, gene therapy 
approaches have been suggested as a means of modifying the patient’s normal cells to be 
more resistant to the drug regimen used to kill the cancer cells (Sorrentino 2004).  The 
incorporation of these drug transporters allow the cells to more effectively efflux the 
chemotherapeutic agents, while the tumor cells lacking the transgene are killed by the 
treatment.     
 While the definitive identification of the gene underlying HU sensitivity of 
HSC/HPCs remains elusive, it is hoped that advances in the annotation of the mouse 
genome and proteome will facilitate the approach outlined in this dissertation and provide 
a relevant blueprint for the discovery of quantitative trait genes that underlie the 
associated QTL.  The identified gene(s) could then potentially be modulated, through 
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either interfering RNA (RNAi)-mediated knock-down or transgene-based overexpression, 
such that HU could be more effectively targeted to specific patient groups.   
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